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Diabetes prevalence increases yearly with an expected increase to 642 million people by the year 
2040. Conventional treatment of diabetes involves insulin therapy and other synthetic drugs. 
However, drawbacks of these forms of treatments include high cost and adverse side effects. There 
is therefore, a renewed focus on the use of plants and plant derived products for treatment due to 
their safety and limited side effects. Oleanolic acid (OA) is a plant derived triterpenoid compound 
that has been shown to suppress expression of genes encoding hepatic gluconeogenic enzymes and 
in so doing inhibits hepatic glucose production. Centella asiatica (L.) Urban (CA), an herbaceous 
plant belonging to the family Umbelliferae, has been traditionally used for the management of 
diabetes. Thus, this study was aimed at investigating the effects of OA and CA on selected enzymes 
of carbohydrate metabolism in muscle and skin of streptozotocin- or 10% fructose-streptozotocin-
induced diabetic Sprague-Dawley rats. Non-diabetic and diabetic rats were treated with OA, 500 
mg/kg of CA, 1000 mg/kg of CA and metformin over 14 days. OA increased HK and PFK activity 
of diabetic animals by 82% and 432% (p < 0.05) in muscle and 17.7% and 71% in skin 
respectively. OA also lowered FBPase activity by 24%. Similarly, 500 mg/kg of CA increased HK 
and PFK activity of diabetic animals by 4.4% and 624% (p < 0.05) in muscle and 11% and 35% 
in skin respectively. OA and CA reduced PFK expression in both muscle and skin of diabetic 
animals. CA also increased GS activity by 346% (p < 0.05) in skin of diabetic animals. Treatment 
with CA decreased ALT and AST levels and reduced damage to muscle fibre and skin epidermis 
of diabetic animals in histological studies. The findings of this study indicate that hypoglycaemic 
effect OA and CA may occur through modulation of glycolysis, gluconeogenesis and glycogen 
synthesis. Tissue damage and structural changes in muscle and skin caused by diabetes may be 






1.1 Overview of diabetes 
The prevalence of diabetes increases yearly with an estimated 415 million people living with 
diabetes worldwide in 2015 and this figure being expected to increase to 642 million people by the 
year 2040 (IDF, 2015). South Africa alone had approximately 2.3 million people living with 
diabetes in 2015 (IDF, 2015). Diabetes is a chronic metabolic disorder characterized by 
hyperglycaemia due to absolute or relative impairment of insulin secretion and /or action (ADA, 
2012). Common symptoms of diabetes include polyuria, polydipsia, polyphagia and sometimes 
results in susceptibility of certain infections. The economic burden of diabetes is highlighted by 
the fact that it accounted for 11% of the global health care expenditure with 80% of the patients 
being from low and middle income countries (IDF, 2013).  
Various studies suggest that hyperglycaemia of diabetes is associated with long term complications 
of diabetes which include vision loss, renal failure, cardiovascular diseases, progression of skin 
diseases (Demirseren et al., 2014) and other macro and microvascular complications (Stratton et 
al., 2000; Singleton et al., 2003; Fowler, 2008). The primary goal of treatment of diabetes is 
therefore to maintain glycaemic control thus reducing hyperglycaemia. Deficiency of insulin or 
impairment of its action can affect the regulation of glycogenic, glycolytic and gluconeogenic 
enzymes exacerbating hyperglycaemia. Conventional treatment of diabetes involves insulin 
therapy and other synthetic drugs which have an anti-hyperglycaemic effect. However, the 
drawbacks of these forms of treatments include high cost, poor compliance and adverse side effects 
(Lebovitz, 2011). There is therefore, a renewed focus on use of plants and plant derived products 
for treatment due to their safety and limited side effects. 
Diabetes is mainly classified into 3 categories: Type-I diabetes, type-II diabetes and gestational 
diabetes. Type-I diabetes is the less common type identified by the absolute lack of insulin 
secretion due to destruction of β-cells of the pancreas. The most common form, Type-II diabetes 
is classified by insulin resistance and reduced insulin secretion. Gestational diabetes is defined as 




1.1.1 Type-I diabetes 
 
Type-I diabetes or insulin dependent diabetes is prevalent in 5-10% of diabetic patients (ADA, 
2012). It is an autoimmune disease in which pancreatic β-cells are unable to produce insulin or 
pancreatic cells are defective leading to lack of or deficient insulin secretion. Genetic 
predisposition, autoimmunity, viral infections and environmental factors are some etiological 
aspects involved in the development of the disease (Muthukrishnan et al., 2007). The human 
leukocyte antigen (HLA) region on chromosome 6 is the major site susceptible to genetic variation 
that contributes to the risk of development of this disease (Brorsson et al., 2010). Some patients 
present with ketoacidosis when the disease first manifests itself (Rother, 2007). Most of type-I 
diabetes is classified as immune mediated where the loss of insulin producing β-cells is mediated 
by T-cells involved in autoimmune attack (Rother, 2007). The destruction of β-cells occurs over 
long periods of time but peak prevalence typically occurs during puberty. There is currently no 
known method available to prevent this chronic disorder thus lifelong treatment with exogenous 
insulin is required for survival. 
1.1.2 Type-II diabetes 
 
Type-II diabetes, also known as non-insulin dependent diabetes, is the most common form of 
diabetes that comprises of 90% of diabetes cases worldwide (Xing  et al., 2009). It is characterized 
by elevated blood glucose levels due to reduced secretion of insulin (Stumvoll et al., 2005) and by 
tissue specific resistance to insulin resulting in inefficient absorption of glucose into liver, muscle 
and adipose tissues. The precise cause of type-II diabetes is not yet known but may be associated 
with genetic susceptibility (Kahn et al., 1996) and environmental factors (Figure 1.1) which 
include obesity, physical inactivity, diet and age. These features amplify the chances of individuals 
developing the disease (Ling and Groop, 2009). Although commonly affecting adults, over the 
years, type-II diabetes has become more prevalent in children and young adults. The most 







Figure 1. 1: Pathogenesis of type-II diabetes 
1.1.3 Gestational diabetes  
 
Gestational diabetes is defined as a glucose intolerance of varying degrees with onset or first 
manifestation during pregnancy (Horvath et al., 2010). Statistics show that gestational diabetes 
presents itself in almost 14% of pregnancies (Kim et al., 2002). This form of diabetes not only 
causes health complications for the parent, but also for the child during pregnancy and birth 
(Metzger et al., 2008). These complications include bone fractures and hypoglycaemia, caesarian 
section, pre-eclampsia, birth injuries, need for neonatal care and hyperbilirubinemia (Metzger et 
al., 2008). Long term complications of these infants includes the risk of impaired glucose control 
(Plagemann et al., 1997a) which may later result in obesity (Plagemann et al., 1997b). 
Some patients with gestational diabetes continue to be hyperglycaemic even after delivery and are 
at risk of developing type-II diabetes years later (Kim et al., 2002; Bellamy et al., 2009). Studies 
have shown that pregnant women who are obese are more at risk of developing gestational diabetes 




diabetes significantly reduces the risk of mortality in infants and improves the quality of life of the 
women (Crowther et al., 2005). 
1.1.4 Complications due to diabetes 
 
Although originating from different pathogenic causes, both type-I and II diabetes are 
characterized by hyperglycaemia leading to microvascular and macrovascular complications. 
Microvascular complications include diabetic retinopathy, nephropathy and neuropathy. Diabetic 
retinopathy is known to be the leading cause of new cases of blindness in adults (CDC, 2011) 
while nephropathy is the leading cause of kidney failure in diabetic patients (CDC, 2011). In 2011, 
44% of new cases of kidney failure occurred in those with diabetes in USA (CDC, 2011). 
Neuropathy is defined as a group of diseases or a disease that affects nerves with more than half 
of patients with diabetes being affected in their lifetime resulting in loss of or altered sensation and 
pain in their legs and feet. This contributes to the potential risk of diabetes-related foot problems 
that are difficult to treat and in extreme cases may lead to amputation. It is estimated that 60% of 
lower limb amputations occur in patients with diabetes (CDC, 2011). Macrovascular complications 
arise from changes in larger blood vessels which result in cardiovascular and cerebrovascular 
disorders leading to myocardial infarctions and strokes, respectively. Patients with diabetes present 
a 2 to 4 times higher increase in strokes and increase in mortality due to cardiovascular diseases 
than patients without diabetes (CDC, 2011). In 2010, in USA, heart disease and stroke were noted 
to be 1.8 and 1.5 times higher, respectively, amongst patients 20 years or older diagnosed with 
diabetes (CDC, 2014). 
 
1.2 Glucose metabolism  
1.2.1 Glucose metabolism in liver 
 
The liver plays a central role in glucose homeostasis (Wu et al., 2001; Wu et al., 2005) by 
contributing towards hepatic glucose utilization and hepatic glucose production depending on the 
available plasma glucose levels. The liver is responsible for disposing up to 25-35% of the oral 
glucose load (Meyer et al., 2002) and achieves glucose homeostasis by producing glucose through 




Hepatic glucose homeostasis is mainly controlled by hormones insulin and glucagon. Insulin 
increases activity of glycolysis and glycogenesis while inhibiting gluconeogenesis and 
glycogenolysis in the liver (Aronoff et al., 2004; Nuttall et al., 2008). Glucagon on the other hand 
has the opposite effect. Epinephrine is mainly used when glucagon response is impaired (Aronoff 
et al., 2004). In the fasting state, the liver provides energy to the body through glycogenolysis and 
gluconeogenesis to restore blood glucose concentrations (Moore et al., 2012). The breakdown of 
glycogen is catalyzed by glycogen phosphorylase. The product of glycogen phosphorylase, 
glucose-1-phosphate is further converted. by phosphoglucomutase, to glucose-6-phosphate which  
in turn is converted to glucose (Manabe et al., 2013). After feeding, hepatic glucose production is 
suppressed and glucose is utilized through glycolysis and stored as glycogen in the liver. Animals 
with type-II diabetes show increased hepatic glucose production due to suppressed insulin levels 
(Bogardus et al., 1984; Rizza, 2010). Administration of insulin decreases glucose levels of STZ- 
induced diabetic rats in liver (Bogardus et al., 1984). Studies have demonstrated reduction of 
hepatic blood glucose as a potential treatment of diabetes (Morral, 2003). 
 
1.2.2 Glucose metabolism in skeletal muscle  
 
Skeletal muscle is one of the major tissues responsible for carbohydrate and lipid metabolism in 
the body (Kelley and Goodpaster, 2001) and is responsible for 75% of glucose disposal under 
insulin stimulated conditions (Saltiel and Kahn, 2001). It therefore plays a major role in regulation 
of blood glucose and storage of glycogen. 
Insulin stimulates translocation of GLUT4 glucose transporters from the intracellular pool to the 
cell surface of skeletal muscle which then facilities glucose entry into the cell (Rowland et al., 
2011). This rate limiting step controls the rate at which glucose is utilized in skeletal muscle 
(Dimitriadis et al., 2011). After transport, glucose is introduced into the glycolytic cycle through 
phosphorylation by hexokinase. The product of hexokinase, glucose-6-phosphate is further 
metabolized downstream in glycolysis or channeled towards glycogen synthesis (Mizgier et al., 
2014). In glycogenesis, Glucose-6-phosphate is converted to glucose-1-phosphate by 
phosphoglucose isomerase. Glucose-1-phosphate is converted to UDP-glucose which is 




6-phosphate is further metabolized, providing substrates for energy production (Guo et al., 2012). 
Both glycolysis and glycogenesis are stimulated by insulin in skeletal muscle (Dimitriadis et al., 
2011). The rate of glycolysis and glycogenesis is impaired in skeletal muscle of STZ -induced 
diabetic animals through inhibition of hexokinase, phosphofructokinase (Da Silva et al., 2010) and 
glycogen synthase (Jensen et al., 2012).  
1.2.3 Role of skin in glucose metabolism 
 
The skin functions as a biological boundary between the inner and outer environment of the body. 
This organ is responsible for various protective functions and is also involved in absorption, 
secretion of electrolytes, and regulation of heat and water. Since all these functions require energy, 
various pathways are likely to be involved in the generation of energy. Although literature suggests 
that little is known about such pathways, there has been evidence of amino acid metabolism, 
oxygen uptake and carbon dioxide production (Decker, 1971). 
The presence of glycolysis has also been partly recognized through the presence of hexokinase 
(Halprin and Ohkawara, 1966b) and phosphofructokinase (Kondo and Adachi, 1971) in the 
epidermal layer of the skin, while others showed the presence of glucose metabolism by showing 
the presence of intermediate products in skin slices (Cruickshank et al., 1957; Bernstein and Sweet, 
1959). Gluconeogenic enzymes have also been demonstrated in rat skin although the activities of 
fructose-1,6-bisphosphatase, pyruvate carboxylase and phosphoenolpyruvate carboxykinase were 
twenty times lower compared to liver on wet-weight basis (Peters and White, 1976). Diabetes 
results in several skin related complications including disturbances in wound healing properties 
(Knas et al., 2013). Alloxan-induced diabetic animals have been shown to have decreased skin 
epithelium thickness (Tanga et al., 2003). Diminished hexokinase activity has been observed in 





Figure 1.2: Summary of pathways involved in glucose metabolism including glycolysis, 
gluconeogenesis, glycogenesis and glycogenolysis 
 
1.2.3 Glycolytic enzymes 
 
Glycolysis is a metabolic pathway that involves the breakdown of glucose after being taken up by 




2011). The pathway also provides substrates for other pathways such as polyol pathway, pentose 
phosphate pathway, glycogenesis and lipogenesis. Regulatory steps in glycolysis include glucose 
uptake by glucose transporters, glucose phosphorylation by hexokinase, conversion of fructose-6-
phosphate into fructose-1,6-phosphate by phosphofructokinase and pyruvate production by 
pyruvate kinase (Figure 1.2) (Guo et al., 2012). Regulation of these rate limiting enzymes is often 
linked to regulation of glucose metabolism and therefore glycaemic control (Guo et al., 2012). 
1.2.3.1 Hexokinase 
Hexokinase (HK) catalyzes the activation of glucose through phosphorylation in an ATP-
dependent reaction (Wilson, 2003). The product of this enzyme can be channeled into various 
pathways including the pentose phosphate pathway depending on tissue specific metabolic 
requirements (Figure 1.3). 
HK exists as multiple isoenzymes each with similar properties but differentiated from one another 
through ion exchange chromatography or electrophoresis (Katzen and Schimke, 1965). Genetic 
evolution suggests that the enzyme evolved through duplication and fusion of ancestral HK 
resulting in its dimeric form found in multicellular organisms. The isoenzymes are distinguished 
as Type- I, -II, and -III and type-IV. Type-I is dominant in brain and kidney, type-II in muscle and 
type-III is mainly found in the liver (Grossbard and Schimke, 1966). Similar properties shared by 
these three isoenzymes include a molecular weight of approximately 100 kDa each comprised of 
two 50 kDa subunits, a high affinity for glucose, allosteric inhibition by the reaction product, 
glucose-6-phosphate and optimum pH of between 7.8 and 8.8 (Grossbard and Schimke, 1966). 
The three isoforms can however be distinguished from each other on the basis of different 
stabilities in heat and proteolytic activation; different Km values for glucose and ATP and also 
different Ki values for ADP and glucose-6-phosphate (Grossbard and Schimke, 1966). Type-IV 
also known as Glucokinase is however predominantly found in the liver and has a molecular 
weight of 50 kDa, low affinity for glucose and is not subject to feedback regulation by glucose-6-





Figure 1.3: Channeling of the product of hexokinase as substrate for a variety of pathways. 
Adapted from (Wilson, 2003). 
Glucose-6-phosphate, the product of the enzyme serves as primary precursors for different 
metabolic pathways such as glycolysis, glycogenesis and pentose phosphate pathway (Figure1.3). 
Since HK plays an integral role in glucose homeostasis, various studies have looked at its 
modulation as a means of overall glycolysis regulation in diabetes. Several studies have shown 
that HK activity is diminished in diabetic animals (Katzen et al., 1970; Gardiner et al., 2007; Da 
Silva et al., 2010). Katzen et al. (1970) attributed this due to loss of hexokinase type-II protein 
rather than inhibition by glucose-6-phosphate. The activity of HK type-II returned to normal 
following administration of insulin suggesting that synthesis of HK type-II may be regulated by 
insulin (Katzen et al., 1970). Da Silva et al. (2010) showed that metformin could reverse the 
decreased HK activity in STZ-induced diabetic mice. Increased HK activity has been shown after 









The reaction catalyzed by phosphofructokinase (PFK) is a rate determining reaction that plays a 
key role in glucose metabolism. PFK phosphorylates fructoses-6-phosphate at the first carbon atom 
using ATP as the phosphate donor to form a diphosphate, fructose-1, 6-bisphosphate. This reaction 
is an ATP and Mg2+ dependent reaction that is irreversible under intracellular conditions 
(Schöneberg et al., 2013). The PFK reaction is considered the pacemaker of glycolysis by forcing 
the cell to metabolize glucose rather than converting to another sugar or storing it (Schöneberg et 
al., 2013). 
PFK exists as 3 different polymeric isoforms PFK M ( muscle), L ( liver ) and P ( platelets) which 
are located on chromosome 1, 21 and 10, respectively, with a molecular weight of approximately 
85 kDa in humans (Vora and Francke, 1981; Dunaway et al., 1988; Sola‐Penna et al., 2010). The 
PFK gene is a derivative of the prokaryote gene that has undergone mutations such as gene 
duplication, in tandem fusion and divergence. As a result of these mutations, the mammalian gene 
contains an allosteric site for inhibitory ATP and an activator site for fructose-2,6-bisphosphate 
not found in the bacterial gene (Li et al., 1999; Sträter et al., 2011). Expression of the enzyme 
isoforms is tissue specific with PFKM the only isoform expressed in all tissue types while skeletal 
muscle is the only tissue that expresses one form of the enzyme (Dunaway et al., 1988). 
PFK is known to be a complex oligomeric structure that contains different forms of the enzyme, 
mainly dimers and tetramers as the monomers tend to be highly unstable. The balance between the 
dimers and tetramers correlate with the regulation of the enzyme. Dimers correlate with low 
catalytic activity however when polymerized form fully active tetramers, displaying high catalytic 
activity (Luther et al., 1986; Zancan et al., 2008). Equilibrium between the different forms of the 
structure is stimulated by the change in physical and chemical conditions such as pH, temperature, 
concentration of the enzyme and allosteric ligands (Luther et al., 1986). 
Fructose-2,6-bisphosphate (F2,6BP), the product of PFK-2 is a powerful activator of PFK and 
overcomes ATP inhibition of the enzyme (Hers and Van Schaftingen, 1982; Zancan et al., 2008). 
The enzyme may also be allosterically regulated by metabolites such as citrate, drugs and 
intracellular proteins (Sola‐Penna et al., 2010). Insulin stimulates the phosphorylation of PFK 




al., 2010). Studies have shown that PFK activity decreases in liver, muscle and heart of diabetic 
animals (Da Silva et al., 2010; Da Silva et al., 2012). 
1.2.3.3 Pyruvate kinase 
 
The reaction catalyzed by pyruvate kinase (PK) is an irreversible (under physiological conditions) 
rate determining reaction in glycolysis. The enzyme catalyzes the reaction of phosphoenolpyruvate 
and ADP to form pyruvate and ATP, requiring monovalent (K+) and divalent (Mg2+) cations for 
its activity (Yamada and Noguchi, 1999). The product, pyruvate, feeds into various metabolic 
pathways downstream making it an important control point in glycolysis (Muñoz and Ponce, 
2003).  
PK is a 60 kDa tetramer, evolutionarily conserved enzyme that exists as four isozymes in 
mammalian tissues, each with different kinetic properties depending on tissue specific 
requirements. The isozymes have similar structure but differ in their gene expression and 
regulation. The L type is predominantly expressed in liver, R type in red blood cells, M1 type in 
skeletal muscle as well as brain and M2 type in embryonic tissue. These four isozymes are encoded 
by two genes that are present in humans, PKLR and PKM genes. The PKLR gene encodes both 
the L and R isoenzymes through the use of different promoters (Noguchi et al., 1987). The PKM 
gene encodes both M1 and M2 isoenzymes which differ by splicing at position 9 or 10 of exon, 
respectively (Figure 1.4) (Noguchi et al., 1986; David et al., 2010).  
Each isoenzyme has different kinetic properties specific for different metabolic requirements of 
each specific tissue. The M1 type seems to lack any allosteric control and the presence of hormones 
and diet seem to have no influence on the quantity of enzyme present hence it is constitutively 
expressed (Muirhead et al., 1986) while the M2, L and R types are allosterically regulated through 
hormonal and dietary control. Pyruvate kinase is regulated by its substrate phosphoenolpyruvate, 
by feedforward activation of upstream intermediate Fructose-1,6-bisphosphate and feedback 
inhibition by ATP (El-Maghrabi et al., 1982; Yamada and Noguchi, 1999; Muñoz and Ponce, 
2003).  
Pyruvate kinase activity has been shown by various studies to be decreased in alloxan- and STZ-




2014). This has been attributed to diminished glucose metabolism and ATP production. The 
activity of the enzyme increased upon administration of insulin (Yamada and Noguchi, 1999). 
 
Figure 1. 4: Isoenzymes of  pyruvate kinase encoded for by two different genes, adapted from (Jurica 
et al., 1997) 
 
1.2.4 Gluconeogenesis enzymes 
 
Gluconeogenesis is the anabolic pathway of glucose production from precursors such as lactate, 
pyruvate and alanine. Key regulatory enzymes include phosphoenolpyruvate carboxykinase 
(PEPCK), fructose-1, 6-bisphosphatase (FBPase) and glucose-6-phosphatase (G6Pase) (Figure 
1.2). These enzymes are regulated by insulin at the transcriptional level. Hence involvement of 






1.2.4.1 Phosphoenolpyruvate carboxykinase 
 
Phosphoenolpyruvate carboxykinase (PEPCK) is the first rate limiting enzyme in gluconeogenesis 
(Rognstad, 1979). The enzyme catalyzes the conversion of oxaloacetate into phosphoenolpyruvate 
with release of carbon dioxide (Croniger et al., 2002). It requires the divalent manganese ion for 
activity and GTP or ITP as a phosphate donor (Croniger et al., 2002). This reaction is important 
in gluconeogenesis because it is thought to be a rate limiting reaction since it can bypass the 
thermodynamically unstable reaction catalyzed by pyruvate kinase in glycolysis (Burgess et al., 
2007). 
PEPCK exists as both mitochondrial (PEPCK-M) and cytosolic (PEPCK-C) forms with both 
isoenzymes showing 63% sequence identity. The two isoforms have molecular weights of 
approximately 69 kDa (Zimmer and Magnuson, 1990). PEPCK-M exists in liver before birth while 
PEPCK-C is only present at birth where it is thought to be linked to the beginning of 
gluconeogenesis and glucose homeostasis in the liver (Ballard and Hanson, 1967). Transcription 
of the enzyme is stimulated by glucagon (Lamers et al., 1982) and glucocorticoids while it is 
inhibited by insulin (Sasaki et al., 1984). 
Diet and hormones such as glucocorticoids and insulin control only PEPCK-C gene transcription 
while PEPCK-M is constitutively expressed (Tilghman et al., 1974). Apart from its role in 
gluconeogenesis, PEPCK-C is also involved in three more major pathways including 
glyceroneogenesis (Reshef et al., 2003), synthesis of serine (Kalhan and Hanson, 2012) and 
conversion of glutamine and glutamate to phosphoenolpyruvate (Montal et al., 2015). A role in 
cataplerosis has also been suggested where PEPCK-C breaks down carbon skeletons from amino 
acids which are then used in biosynthetic pathways such as gluconeogenesis in liver and kidney 
(Owen et al., 2002). 
The role of PEPCK-C in glucose metabolism highlights its importance in diabetes as one of the 
potential therapeutic targets for anti-diabetic drugs. PEPCK-C activity is increased in diabetic 
animals (Dayer et al., 2009; Dayer and Dayer, 2010). Various studies have explored the use of 
inhibitors as a pharmacological potential of managing diabetes. Some have investigated post 




investigated the use of amino acids such as glutamate (Dayer and Dayer, 2010) or tryptophan 
(Alvares and Ray, 1974) as inhibitors of PEPCK-C activity. 
1.2.4.2 Fructose-1, 6-bisphosphatase 
 
Fructose-1, 6-bisphosphatase (FBPase) is a 37 kDa homotetramer enzyme involved in 
dephosphorylation of fructose-1,6-phosphate yielding fructose-6-phosphate and an inorganic 
phosphate (Zhang et al., 2010). The enzyme requires divalent cations such as Mg2+, Mn2+ and Zn2+ 
for its activity and monovalent cations such as K+ may further enhance enzyme activity. When 
coupled with PFK, FBPase is able to control the recycling between fructose-6-phosphate and 
fructose-1, 6-bisphosphate to aid in regulation of glycolytic/gluconeogenic cycle (Rashid et al., 
2002). 
FBPase is regulated directly by AMP and F2,6BP, and indirectly by glucagon and insulin (Iversen 
et al., 1997). F2,6BP (a powerful activator of PFK) is a competitive inhibitor of the FBPase 
substrate, fructose-1,6-bisphosphate while AMP inhibits FBPase at its allosteric site (Van 
Schaftingen and Hers, 1981; Rakus et al., 2005). AMP inhibition is thought to be a mechanism of 
protecting the muscle against the loss of energy due to cycling between PFK and FBPase. 
FBPase is a rate-limiting enzyme in the gluconeogenic pathway that plays a key role in the overall 
regulation of this pathway. Studies have shown that FBPase is involved in glucose-stimulated 
insulin secretion in β-cells (Kebede et al., 2008; Zhang et al., 2010). FBPase is expressed in β-
cells where it acts as a regulator by controlling glucose sensing and insulin secretion. 
Overexpression of β-cells resulted in reduced insulin secretion (Kebede et al., 2008). This suggests 
that the enzyme might play a role in β-cell dysfunction during pathogenesis of diabetes. Studies 
suggest that FBPase activity is increased in liver, kidney and skeletal muscle of alloxan-induced 
diabetic rats (Alam et al., 2014). Administration of hypoglycaemic agents such as eugenol 
(Srinivasan et al., 2014) and fraxetin (Murali et al., 2013) also resulted in decrease in enzyme 
activity in diabetic rats. FBPase is regarded as a target for drugs that would inhibit endogenous 
glucose production without directly affecting glycogenolysis, glycolysis, and the tricarboxylic acid 





1.2.5 Glycogen metabolism 
 
Glycogen is a form of stored glucose and glycogen metabolism involves two pathways, 
glycogenesis and glycogenolysis (Figure 1.2). Glycogen structure is characterized by straight 
chains of glucose linked by α-1,4 glycosidic bonds that branch every 10 to 13 residues by α-1, 6 
linkages. Glycogen is stored in liver and skeletal muscle with the latter being a major site of 
glucose disposal (Jensen and Lai, 2009). The main function of glycogen is to maintain 
physiological blood glucose concentrations with the liver being the only major tissue that 
contributes directly towards the release of glucose in the blood (Nuttall et al., 2008). Glycogen in 
skeletal muscle fails to directly contribute to free glucose in the blood due to the lack of the enzyme 
glucose-6-phosphatase. Instead, skeletal muscle contributes indirectly by the breakdown of 
glycogen through conversion into lactate which can be transported to the liver therefore 
contributing towards glycaemic control. Glycogen concentrations are regulated by glycogen 
synthase and glycogen phosphorylase activity. 
1.2.5.1 Glycogen synthase 
 
Glycogen synthase (GS) is the final enzyme in the synthesis of glycogen that catalyzes the α-1, 4-
glycosydic linkage of UDP-glucose to glycogen and is a major rate limiting enzyme in glycogen 
synthesis (Jensen et al., 2006). The enzyme is regulated allosterically and by covalent 
modifications. Phosphorylation of GS occurs at nine sites leading to deactivation of the enzyme 
during post translational modifications. Two of the sites (2 and 2a) are located at the amino 
terminal while the remaining (3a-c,4,5,1a-b) are located in the carboxyl terminal of GS. 
Phosphorylation at sites 2,2a,3a and 3b are reported to be the major sites involved in regulating 
enzyme activity in vitro (Skurat et al., 1994) and in vivo (Skurat et al., 2000; Højlund et al., 2009). 
Insulin activates GS through protein kinase B-mediated phosphorylation and inactivation of 
glycogen synthase kinase-3 (GSK-3). Phosphorylation of GSK-3 decreases its activity resulting in 
decreased phosphorylation activation of GS (McManus et al., 2005; Bouskila et al., 2008). GS is 
allosterically activated by glucose-6-phosphate (Bouskila et al., 2010) while ATP acts as an 
inhibitor by lowering the enzyme’s affinity for UDP-glucose (Solling, 1979). Studies have shown  




1.2.5.2 Glycogen phosphorylase 
 
Glycogen phosphorylase (GP) is a rate limiting enzyme that catalyzes the breakdown of the 
terminally linked glucose residues on glycogen into glucose-1-phosphate which subsequently 
leads to the formation of glucose (Manabe et al., 2013). Three isoforms that are known to exist in 
skeletal muscle; liver and brain are respectively located on chromosomes 11, 20 and 14. All 3 
isoforms having a molecular weight of approximately 97 kDa made up of 842 residues (Monod et 
al., 1965)and pyridoxal-5-phosphate acts as a cofactor of the enzyme. 
 
GP is regulated through allosteric control by AMP or IMP and through phosphorylation and 
dephosphorylation (Johnson, 1992). This allows the enzyme to exist as two interconvertible forms. 
GPa is the phosphorylated form with high activity and high affinity for the substrate. This is known 
as the relaxed (R) state. GPb is its unphosphorylated form that has low activity and low affinity 
for its substrate. This is known as the tense (T) state (Johnson, 1992). Both forms are required for 
balance between inactive T state and active R state. In the resting muscle, GP exists as GPb which 
can be activated through phosphorylation by phosphorylase kinase on ser14 or through allosteric 
binding of AMP or IMP converting it to GPa (Villar-Palasi and Wei, 1970). Dephosphorylation of 
GPa is catalyzed by phosphorylase phosphatase (Villar-Palasi and Wei, 1970). GP is allosterically 
inhibited by glucose, glucose-6-phosphate, fructose-1-phosphate, ADP, xanthines and ATP 
(Figure 1.5). These  hinder the degradation of glycogen by disabling balance between the T state 







Figure 1. 5: Regulation of glycogen phosphorylase, (Adapted from Nuttall et al., 2008).  
 
Studies have shown that STZ- induced diabetic animals are characterized by increased levels of 
GPa (Docsa et al., 2011). The use of GP inhibitors has been explored as possible drugs for 
controlling type-II diabetes since they may improve glucose tolerance, prevent glycogen 
breakdown and stimulate glycogen synthesis (Oikonomakos et al., 2000; Baker et al., 2005; Nagy 
et al., 2013) 
1.3 Treatment of Diabetes 
1.3.1 Conventional treatment of diabetes 
 
Although diabetes cannot be cured, it can be managed through tight glycaemic control thus 
reducing complications associated with the disease. This is achieved mainly through medication, 
lifestyle changes or a combination of both (Norris et al., 2002). At present, the management of 
Type-I diabetes involves the use of insulin therapy, diet and exercise. Dietary modifications, 
physical exercise, insulin therapy and oral drugs such as sulphonylureas, biguanides, alpha-






Type-I diabetes is conventionally treated with insulin therapy. Insulin is a 6 kDa peptide that is 
secreted by pancreatic β-cells in response to an increase in blood glucose levels. Insulin or insulin 
analogs are required to stimulate uptake or entry of glucose into tissues such as liver and skeletal 
muscle where glucose is converted into energy or  it is stored as glycogen thus clearing any excess 
glucose (Stapleton, 2000). Insulin also stimulates glycolysis and glycogenesis but inhibits 
gluconeogenesis and glycogenolysis thus reducing glucose production in hepatic tissue 
(Cummings, 2006). Insulin  also regulates transcription of genes of several key enzymes associated 
with carbohydrate and fatty acid metabolism (O'Brien et al., 1990).  
The use of insulin however has its own shortcomings, which makes it less than ideal for 
management of diabetes. The most common side effect of insulin therapy is hypoglycaemia 
(Friedewald et al., 2008) and weight gain (Mäkimattila et al., 1999). Weight gain may result in 
obesity which is known to cause insulin resistance and one of the risk factors of cardiovascular 
diseases and hypertension (Landsberg et al., 2013). This makes insulin a less than ideal form of 
treatment as it may lead to more complications than the original problem of diabetes. Other side 
effects include insulin allergy (Wu et al., 2013), auto antibodies (Yu et al., 2012), insulin resistance 
(Gambineri et al., 2012) and altered metabolic control (Nolan et al., 2015). 
Figure 1.6 summarizes the oral drugs used as glucose lowering agents in the management of type 
-II diabetes. These drugs include sulphonylureas, meglitinides, α-glucosidase inhibitors, 





Figure 1. 6:Treatment of diabetes using conventional drugs, (Adapted from Stumvoll et al., 2005). 
GLP1 = glucagon-like peptide 1. DPP-IV = dipeptidyl peptidase IV. 
 
Sulphonylureas and meglitinides 
Sulphonylureas and meglitinides stimulate the secretion of insulin in β-cells (Figure 1.6) (Sunaga 
et al., 2001). This occurs by binding to a sulphonylurea SUR receptor on pancreatic β-cells leading 
to closing of ATP-sensitive potassium channels. The closing of these channels results in decrease 
in potassium influx and depolarization of β-cell membrane which in turn results in an uptake of 




secretory granules containing insulin to the cell surface and release of insulin through exocytosis 
(Proks et al., 2002). Meglitinides act on potassium dependent ATPase enzyme leading to the 
closure of the ATP sensitive potassium channel similarly to sulphonylureas (Sunaga et al., 2001). 
Sulphonylureas are classed into first and second generations based on when they became available. 
First generation sulphonylureas include acetohexamides, chlorpropamides, tolazamides and 
tolbutamides. Second generation sulphonylureas include glimepirides, glipizides and glyburides 
(Proks et al., 2002). Both generations of drugs have the same level of efficacy but second 
generation sulphonylureas are considered more potent and safer than first generation making them 
more commonly prescribed (Philippe and Raccah, 2009). Meglitinides consist of repaglinide and 
nateglinide (Sunaga et al., 2001).  
The advantages of using sulphonylureas include relative affordability and their ability to reduce 
microvascular complications (UKPDS, 1998). The adverse effects however may outweigh the 
advantages of these drugs. The side effects of sulphonylureas and meglitinides include 
hypoglycaemia and weight gain (UKPDS, 1998; Nauck et al., 2007) Since sulphonylureas are able 
to act at low concentrations of plasma glucose and over a long period of time, risks of potential 
hypoglycaemia has been shown in a number of studies (Bodmer et al., 2008; Ragia et al., 2014). 
The loss of insulin secretory capacity over time leading to the eventual exhaustion of β-cells often 
referred to as secondary failure also occurs when using these drugs (Polo et al., 1998; Jiang et al., 
2016).  
Alpha-glucosidase inhibitors 
Alpha-glucosidase inhibitors include acarbose and miglitol. They w act by decreasing the rate of 
carbohydrate absorption and digestion by competitively inhibiting the action of enzymes, primarily 
α-glucosidase in the small intestine (van de Laar et al., 2005). An α -glucosidase is an enzyme 
located in the brush border of the epithelium of the small intestine where it breaks down 
disaccharides and other carbohydrates into absorbable glucose. Alpha-amylase hydrolyses 
complex starch. Alpha-glucosidase inhibitors competitively inhibit these enzymes by binding to 
the carbohydrate binding region of the enzymes causing a delay in carbohydrate absorption and 




The advantages of α-glucosidase inhibitors include their ability not to cause hypoglycaemia or 
weight gain (Holman et al., 1999) as seen is other oral hypoglycaemic agents. Studies have shown 
that acarbose could reduce the risk of progression from impaired glucose tolerance to type-II 
diabetes (Chiasson et al., 2004). It has also been shown to reduce the risk of cardiovascular disease 
and hypertension events in patients with impaired glucose tolerance (Chiasson et al., 2003; 
Chiasson et al., 2004; Hanefeld et al., 2004). The side effects of these drugs however include 
gastro-intestinal symptoms such as diarrhoea and abnormal dysfunction and flatulence (Hsiao et 
al., 2006). Abnormal liver function has also been reported in some cases (Hsiao et al., 2006). 
Thiazolidinediones 
There are three types of drugs found in this class of anti-diabetic agents commercially available 
which include troglitazone, pioglitazone and rosiglitazone. Thiazolidinediones are antidiabetic 
agents that enhance insulin sensitivity. They increase glucose uptake and utilization in peripheral 
tissues and reduce hepatic glucose production (Miyazaki et al., 2001). Thiazolidinediones are 
ligands that act on the peroxisome proliferator activated receptor (PPAR-γ) that are found in 
skeletal muscle and hepatic cells and in predominantly adipose cells (Lehmann et al., 1995). 
Activation of PPAR-γ in adipocytes induces expression of genes involved in insulin signaling 
cascade such as GLUT4 therefore improving insulin sensitivity (Hammarstedt et al., 2005). 
Thiazolidinediones have been shown to achieve glycaemic control in patients with type-II diabetes 
when used as a monotherapy or in combination with other drugs such as sulphonyureas or 
metformin. The side effects however outweigh the benefits of using thiazolidinediones. These 
include weight gain, hepatotoxicity (Marcy et al., 2004), increase in myocardial infarctions, risk 
of heart failure (Nissen and Wolski, 2007) and bone fracture incidences (Kahn et al., 2008). The 
risk of bladder cancer has also been linked to the use of thiazolidinediones over a 2 year period 
(Lewis et al., 2011). 
Dipeptidyl peptidase-4 inhibitors 
Dipeptidyl peptidase-IV (DPP-IV) inhibitors are a class of antidiabetic agents that increase the 
half-life of incretin hormones, glucagon-like peptide-1 (GLP1) and glucose dependent 




al., 2005). GLP-1 and GIP are produced in response to meals, improves β- cell function by 
stimulating insulin secretion and suppressing the release of glucagon (Ahrén et al., 2004). There 
is evidence of DPP-IV delaying gastric emptying and increasing mass of islet cells (Egan et al., 
2003; Aschner et al., 2006). Common available DPP-IV inhibitors include sitagliptin and 
vildagliptin (Thornberry and Gallwitz, 2009).  
DPP-IV inhibitors are used as a monotherapy or as a combination with other agents such as 
metformin or sulphonylureas (Aschner et al., 2006; Charbonnel et al., 2006). DPP-IV inhibitors 
however, exhibit side effects on the upper respiratory tract causing infections (Lambeir et al., 
2003). 
Biguanides 
This class of drug includes burformin, phenformin and metformin. The biguanide metformin is the 
most common drug used for treatment of type-II diabetes (Boussageon et al., 2012) although the 
mode of action is unclear. Metformin enhances insulin sensitivity in hepatic and peripheral tissue 
(Stumvoll et al., 1995). It inhibits gluconeogenesis and stimulates glycolysis by lowering glucose 
production in liver and increasing glucose disposal in peripheral tissues respectively (Musi et al., 
2002). Metformin also decreases absorption of glucose in the intestine (Ikeda et al., 2000). 
Metformin lowers glucose levels without increasing insulin secretion. 
Since insulin secretion is not affected, metformin does not cause hypoglycaemia when used as a 
monotherapy treatment (Bodmer et al., 2008). Another benefit of using metformin is that it does 
not cause weight gain (Mäkimattila et al., 1999) and also improves lipid profile . The efficacy of 
metformin diminishes over time although why this happens is still unclear. The use of phenformin 
has since been discontinued because it caused lactic acidosis (Bergman et al., 1978). Nausea, 
diarrhea and abdominal pains are the most common side effects associated with the use of 
metformin (Moghetti et al., 2000). 
Although these anti-diabetic agents can exhibit glycaemic control, unfortunately none of them can 





1.3.2 Treatment using herbal extracts 
 
The diverse use of plants in traditional medicine has been practiced by various countries, cultures 
and tribal groups since ancient times. Herbal medications have been used in the treatment of a 
wide variety of ailments all over the world (Adbullahi, 2011). A large population of developing 
countries still depend on traditional medicine derived from plants (Adbullahi, 2011). However, the 
efficacy and mechanism of action of some of these extracts are yet to be elucidated. Many plants 
contain phytoconstituents such as glycosides, saponins, flavonoids and terpenoids which have been 
shown to have antidiabetic potential. Over 800 plants have been identified for their potential 
antidiabetic ability (Daisy and Eliza, 2007), but only a few of these plants have been proven to 
have significant effect (Jia et al., 2009). 
Some proposed mechanisms of plant active ingredients include the ability to stimulate insulin 
secretion (Keller et al., 2011), antioxidant effects (Ravi et al., 2004), regulation of enzymes, 
increasing the expression of insulin receptors (Gao et al., 2007) or acting to stimulate the secretion 
of insulin. Their mode of action however is limited by factors which may include that plant extracts 
are made up of different constituents and only a few of those may be therapeutically effective. 
Also, different parts of a plant have different ingredient profiles thus upon extraction may yield 
different active ingredients. Regardless of these factors, these plants need to be investigated for 
their advantages. The use of plants for treating diseases is becoming popular due to their safety, 





1.3.2.1 Oleanolic acid 
 
 
Figure 1. 7: Chemical structure of oleanolic acid (Pollier and Goossens, 2012). 
Oleanolic acid (OA) is a pentacyclic triterpenoid compound (Figure 1.7) prevalent in plants 
belonging to the Oleaceae family, especially olives which serve as the main commercial source of 
oleanolic acid (Sporn et al., 2011). The biologically active compound is usually found with its 
isomer ursolic acid with which it shares its pharmacological properties (Liu, 1995). Common 
functions of OA include protection from pathogens and prevention from water loss (Heinzen et 
al., 1996). An example of this is seen in olive leaves where OA protects against fungal attack 
(Kubo and Matsumoto, 1984). In plants, OA may become conjugated and serve as a defense 
compound against pathogens (Szakiel et al., 2003). 
 
1.3.2.1.1 Pharmacological properties of OA 
 
OA has been used as an over the counter drug for liver diseases such as viral hepatitis due to its 
hepatoprotective effect. Even though its mechanism of action has not yet been fully elucidated, 
OA has been shown to be effective in protecting the liver against chemically induced liver injury 




nuclear accumulation of a key regulator of transcription and detoxifying enzyme known as nuclear 
respiratory factor 2 (Nrf2). This in turn leads to the induction of Nrf2-dependent genes that play a 
role in the protection of the liver (Reisman et al., 2009). Other properties of OA include 
cardioprotective (Mapanga et al., 2012), anti-inflammatory, anti-oxidant (Somova et al., 2003) 
and anti-cancer (Liby et al., 2007; Laszczyk, 2009) effects. 
 
1.3.2.1.2 Hypoglycaemic effects of oleanolic acid 
 
Previous studies have shown that OA has potential hypoglycaemic effects in vitro and in vivo. OA 
has been reported to enhance insulin secretion in pancreatic islet cells in vitro comparable to the 
standard drug, tolbutamide (Teodoro et al., 2008). Syzygium aromaticum, a plant rich in oleanolic 
acid was shown in vitro to limit the expression of hepatic gluconeogenic enzymes 
phosphoenolpyruvate carboxykinase and glucose-6-phosphatase enzymes involved in glucose 
production thus indicating hypoglycaemic activity (Prasad et al., 2005). STZ-induced diabetic 
animals treated with 100 mg/kg b.w. OA were shown to have lowered blood-glucose comparable 
to those treated with the standard drug metformin (Wang et al., 2011). 
1.3.2.2 Centella Asiatica (L.) Urban 
 
 




Centella Asiatica (L.) Urban (CA) is a herbaceous, mildly scented plant belonging to the family 
Umbelliferae known by different vernacular names such as “Gotu kola” in India,” Pohekula” in 
Hawaii, “Indian pennywort” in USA or “Icudwane” in South Africa. The plant has ovoid shaped 
leaves that emerge in clusters and thrives in shady, moist and marshy areas (Figure 1.8). CA is 
native to many tropical and subtropical regions such as India, Australia, Madagascar, Japan, 
Colombia, China, South America as well as South Africa (Verma et al., 1999). The plant is used 
worldwide for its nutritional purposes where it is ingested in food and beverages providing needed 
proteins, minerals and vitamins such as ascorbic acid, thiamine and β-carotene (Gupta et al., 2005; 
Odhav et al., 2007). It may either be consumed raw as a salad or ingested along with sweet potatoes 
or coconut milk to tolerate its bitter taste (Huda-Faujan et al., 2009). 
 
1.3.2.2.1 Phytochemistry of CA 
 
The phytochemistry of CA reveals a rich chemical composition including triterpenes, saponins, 
flavonoids, glycosides, alkaloids essential oils and more (Ling et al., 2000). The triterpene acids 
which include asiatic acid and madecassic acid and their respective triterpene ester glycosides, 
asiaticosides and madecassosides (Figure 1.9) are known to be some of the main biologically active 
components of the plant (Ling et al., 2000). These triterpenes are used as biomarkers of quality 
assessment of the plant (Ling et al., 2000). CA has been revealed to also possess a high degree of 
polyphenols contributed mostly by various flavonoids such as quercetin, kaempferol, catechin and 
naringin which are thought to be involved in the antioxidant activity of CA (Zainol et al., 2003; 
Huda-Faujan et al., 2009; Reihani and Azhar, 2012). The plant is also known to be rich in essential 
oils, saponins, alkaloids and amino acids such as serine, alanine, threonine, aspartic acid, glutamic 





Figure 1. 9: Main biologically active components of CA, (Adapted from Orhan 2012). 
Due to its rich chemical composition, CA has been used in folk medicine for the treatment of 
various illnesses and described by some as a “herbal cure all” (Arora et al., 2002). These illnesses 
include jaundice, vomiting, scabies, leprosy, tonsils, diarrhea, skin disorders, asthma, stomach 
disorders, cholera, elephantiasis nerve tonic, hepatitis and many more. Apart from aiding in 
treatment of these illnesses, CA has gained much of its popularity in wound healing, and skin 
disorders as well as memory enhancement (Arora et al., 2002)  
 
1.3.2.2.2 Pharmacological properties of CA 
 
CA has been reported to improve memory and learning in mice during postnatal brain development 
(Rao et al., 2005). In another study, CA was found to ameliorate colchicine- induced memory 
impairment and associated oxidative stress that lead to difficulties in learning and memory ability 
of male Wistar rats. This suggested CA as a prospective treatment of neurodegenerative disorders 




potential in neurological disorders by protecting rat brain from age related oxidative damage when 
administered at those of  300 mg/kg b.w. daily for 60 days (Subathra et al., 2005).  
 
Asiaticosides are involved in wound healing and are known to have vascular effects while 
brahmosides are thought to have effects on the central nervous system (Gohil et al., 2010). Some 
properties of CA include hepatoprotection (Antony et al., 2006) where CA was shown to  
potentially protect the liver against carbon tetrachloride-induced liver damage in male Sprague 
Dawley rats. This was shown through the decrease in the levels serum marker enzymes; aspartate 
amino transferase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)  and 
increase in serum proteins and albumin levels. 
 
1.3.2.2.3 Hypoglycaemic effect of CA 
 
CA has been traditionally used for the management of diabetes in Asia, Indian Ayurvedric 
medicine (Grover et al., 2002) and Africa, specifically Tanzania (Mutayabarwa et al., 2005). Both 
methanol and ethanol extracts of CA showed hypoglycaemic potential in diabetic rats by lowering 
glucose levels in glucose tolerance test. However the methanol extract showed higher 
hypoglycaemic potential than the ethanol extract, suggesting that methanol extraction may enrich 
the active constituents of the plant (Chauhan et al., 2010). Another study showed that diabetic rats 
treated with 50, 100 and 200 mg/kg b.w. of CA daily for 22 days had lower blood glucose levels 
when compared to the standard drug metformin (Rahman et al., 2012). Diabetic rats treated with 
50 mg/ kg b.w. Asiatic acid, a biologically active constituent of CA, has been shown to lower 
plasma glucose levels of STZ- induced diabetic rats. It was also shown to influence the activity of 
glucose-6-phosphatase, fructose-1,6-bispospatase, hexokinase, pyruvate kinase, and glucose-6-
phosphate dehydrogenase as well as glycogen content in liver of diabetic rats (Ramachandran and 









1.4 Rationale of study 
 
Diabetes is characterized by hyperglycaemia and treatment mainly focuses on glycaemic control. 
Several natural plants and plant-derived compounds including CA and OA respectively have been 
investigated and shown to have anti-diabetic potential (Teodoro et al., 2008; Rahman et al., 2012) 
Skeletal muscle accounts for about two thirds of total glucose uptake under insulin stimulated 
conditions (Saltiel and Kahn, 2001). Skin being the largest organ in the body plays a significant 
role in the body’s total glucose metabolism. Glycolysis, gluconeogenesis, glycogenolysis and 
glycogenesis play roles important role in glucose metabolism mainly through regulatory enzymes 
that catalyze the rate limiting reactions in each pathway. An understanding of how OA and CA 
affect the rate limiting enzymes in glucose metabolism is yet to be fully elucidated. Thus, the study 




1.5 Aim and objectives 
Aim 
To determine the effect of OA and CA on key carbohydrate metabolizing enzymes in skeletal 
muscle and skin of streptozotocin-induced type-II diabetic rats. 
Objectives 
1. To determine the activities of hexokinase, phosphofructokinase and fructose-1,6-bisphosphatase 
in diabetic rats after treatment with OA and CA extract using enzyme assays. 
2. To measure the expression of phosphofructokinase and glycogen phosphorylase using SDS- 
PAGE and western blot analysis. 
3. To determine glycogen phosphorylase and glycogen synthase activities; and glycogen content 
in muscle and skin after treatment with OA and CA. 
4. To assess amelioration of tissue damage by carrying out a histological analysis of both muscle 
and skin tissue following treatment with CA. 
5. To assess amelioration of tissue damage by determining serum aspartate transaminase (AST) 













1.6 Outline of the thesis 
This dissertation is comprised of six chapters. The first chapter above is an introductory chapter 
that is composed of an in-depth literature review, rationale of the study and research aim and 
objectives. The literature review encompasses all relevant and recent information about diabetes 
and current oral treatments and their limitations. It includes a review of the known anti-diabetic 
effects of Oleanolic acid and Centella asiatica.  
 
Chapter 2, the Materials and Methods chapter, describes all reagents and methods used to acquire 
the results. This chapter covers the induction of insulin insufficiency as well as insulin resistance 
and insulin insufficiency models of type-II diabetes in male Sprague-Dawley rats obtained from 
the Biomedical Research unit, Westville campus. Enzyme activity assays, western blots and 
histological examinations were carried out on harvested muscle and skin tissues while alanine 
amino transferase and aspartate amino transferase activities were determined in serum Statistical 
analysis was performed using Graphpad software. 
 
Chapter 3 comprises of results obtained from experiments described in the previous chapter. These 
results include enzyme activities, SDS-PAGE, enzyme expressions and histological examinations 
of both muscle and skin samples. 
 
Chapter 4 is the discussion which evaluates the anti-diabetic effects of oleanolic acid and Centella 
asiatica in muscle and skin of streptozotocin-induced diabetic animals. A comparison is also made 
between their effects in the two types of diabetic models used in this study. 
 
Finally, Chapter 5 contains the conclusion, limitations and possible future aspects of the study 








Materials and Methods  
2.1 Materials 
 
2.1.1 Animals  
Male Sprague-Dawley rats weighing (250-300 g) were obtained from Biomedical Research Unit 
at University of KwaZulu-Natal, Westville campus. The animals were fed a standard rat chow diet 
ad libitum (Meadows, Pietermaritzburg, South Africa) and allowed free access to drinking water 
for the entire experimental period. Animals in which diabetes was to be induced to determine the 
effects of Centella asiatica extract were only allowed to drink 10% fructose solution prior to 
induction. Procedures involving animals and their care were conducted per the guidelines of the 
University of KwaZulu-Natal (UKZN) Research Ethics Committee which approved the study 
(Ethical Clearance 112/14/Animal). 
2.1.2 Chemicals 
 
The following reagents were purchased from Sigma Aldrich (through Capital Lab Supplies, New 
Germany, South Africa): Streptozotocin (STZ), dimethyl sulphoxide (DMSO), potassium 
chloride, phenol solution, fructose, glucose, trizma base, ethylene diaminetetraacetic acid (EDTA), 
benzamidine, phenylmethanesulfonylfluoride (PMSF), sodium orthovanadate (Na3VO4), 
aprotinin, triethyl amine (TEA), magnesium chloride(MgCl2), adenosine triphosphate (ATP) ,β-
Nicotinamide adenine dinucleotide phosphate (NADP+), β-Nicotinamide adenine dinucleotide 
(reduced) (NADH), 3-(N-morpholino) propanesulfonic acid (MOPS), 3-(N-morpholino) 
ethanesulfonic acid (MES), uridine diphosphate glucose (UDPG), glucose-6-phosphate, 
radiolabeled glucose-1-phosphate disodium salt hydrate Sodium fluoride (NaF), dithiothreitol 
(DTT), bovine serum albumin (BSA), glycogen, glucose-6-phosphate dehydrogenase, 
phosphoglucomutase, α-glycerophosphate dehydrogenase, triose phosphate isomerase, aldolase, 
bromophenol blue, Glycerol, acrylamide. 
Methanol, ethanol, sodium potassium tartatrate (KNaC4H4O4.H2O), potassium iodide (KI), 




sulphuric acid, and Folin-Ciocalteu phenol reagent were purchased from Merck, Modderfontein, 
South Africa. Sodium dodecyl sulphate (SDS), tris, N, N, N, N-Tetramethlyethylenediamine 
(TEMED),10X Tris/Glycine/SDS buffer, ammonium persulphate, Immun-star TM alkaline 
phosphate substrate, goat anti rabbit-IgG alkaline phosphate conjugate, immun-star TM enhancer 
were purchased from BIORAD, Johannesburg, South Africa. The antibodies anti-Glyceraldehyde 
-3-phosphate dehydrogenase (anti-GAPDH), anti-glycogen phosphorylase (anti-GP) and anti- 
phosphofructokinase were purchased from ABCAM (through Biocom Biotech, Centurion, South 
Africa). Deionized water was used to prepare all reagents. 
2.2 Methods 
2.2.1 Preparation of oleanolic acid 
 
An oleanolic acid (OA) suspension was prepared in a vehicle containing dimethyl sulphoxide 
(DMSO): physiological saline solution (1:2). The OA was first suspended in DMSO and then 
diluted by an equal volume of saline. 
 
2.2.2 Preparation of Centella asiatica extract 
 
Centella asiatica leaves were freshly harvested from the University of KwaZulu-Natal, Westville 
Campus, Durban, South Africa. A photographic voucher specimen (Dladla 2) containing all 
characteristics of the leaves was deposited at the Ward Herbarium at University of KwaZulu-Natal 
for authentication. The leaves were authenticated by Professor Ashley Nicholas at the Department 
of Biology, University of KwaZulu-Natal. Leaves were air-dried and the dried leaf material was 
then ground to fine powder form using a grinder and thereafter soaked in 1L methanol at room 
temperature for 4 days. The extracts were collected in pre-weighted glass bottles and then filtered 
using Whatman no.1 filter paper. Filtrates were evaporated at 60°C in a water bath to remove 
methanol. A 10% yield was obtained from 500 g of dried leaves which yielded 50 g after 






2.2.3 Induction of diabetes 
 
Diabetes was induced by a single intraperitoneal (i.p) injection of streptozotocin (STZ) 40 mg/kg 
body weight dissolved in freshly prepared cold 0.1 M citrate buffer (pH 4.5). This gives insulin 
insufficiency “type-II” diabetic rats that are not insulin resistant. These animals were treated with 
OA for comparison with previous studies (Mukundwa et al., 2016a; Mukundwa et al., 2016b) in 
which STZ at 60 mg/kg body weight was used to induce type-I diabetes. Diabetes was also induced 
by having animals drink 10% fructose for 14 days followed by a single intraperitoneal (i.p) 
injection of streptozotocin (STZ 40 mg/kg body weight) dissolved in freshly prepared cold 0.1 M 
citrate buffer (pH 4.5). This gives type-II diabetic rats that have both insulin resistance and 
insufficiency (Wilson and Islam, 2012). These animals were used for the CA study. Animals with 
a fasting blood glucose concentration of 7 mM to 16 mM after a week of induction were considered 
stable diabetic animals. Fasting blood glucose was measured using a glucometer (Accu-Check 
perfoma, USA). 
 
2.2.4 Treatment of animals 
 
Male Sprague-Dawley rats (250-300 g) used to determine the effects of OA were randomly divided 
into non-diabetic (N) and diabetic (D) groups (Figure 2.1). Non- diabetic animals were further 
subdivided into non-diabetic control animals (NC) and non-diabetic treated with 80 mg/kg b.w. of 
OA (NO). Diabetic rats were subdivided into diabetic control (DC), diabetic rats treated with 80 
mg/kg b.w. of OA (DO) and diabetic groups treated with metformin 300 mg/kg b.w. of metformin 
dissolved in distilled water (DM). The control groups were orally dosed with 3 ml/kg b.w. of 
DMSO: Physiological saline (1:2) daily. Groups treated with OA were orally dosed with 80 mg/kg 
b.w. of OA (Ngubane et al., 2011) while groups being treated with metformin were given 300 
mg/kg b.w. of metformin dissolved in distilled water. All the groups were treated daily for 14 days. 
 
Rats used to determine the effects of CA extract were divided into non-diabetic (N) and diabetic 
rats (D) (Figure 2.2). Non-diabetic rats were grouped as non-diabetic control (NC) while diabetic 
rats were further divided into diabetic control (DC), diabetic rats treated with 500 mg/kg b.w. 




b.w. of metformin (DM). The control groups were orally dosed with 3 ml/kg b.w. of DMSO: 











Figure 2. 2 Experimental design of CA treatment study. Rats drank 10% fructose for 14 days before 
STZ treatment. 
 
2.2.5 Harvesting of blood and tissues 
 
On the 15th day, rats were euthanized by inhalation of an overdose of Isofor anaesthetic (Safeline 
Pharmaceuticals, South Africa). Rats were bled by cardiac puncture (Code: RCBP) and blood 
collected into thrombin-coated tubes and stored in ice to be processed to obtain serum. A Heraeus 
Labofuge 200 Centrifuge (Thermoscientific, USA) operated at 3000 rpm for 10 minutes was used 
to obtain serum from blood. Skeletal muscle and skin tissue were harvested, snap frozen in liquid 
nitrogen and stored at -20°C for further analysis. For histological analysis both skeletal muscle and 




2.2.6 Tissue processing 
2.2.6.1 Tissue processing for enzyme activity assays 
 
Tissues were processed by methods described by Ngubane et al. (2011) with modifications. An 
OMNI TH2 tissue homogenizer (NW Kennesaw, GA, USA) operated at 35 000 rpm was used to 
homogenise skeletal muscle (125 mg/ml) and skin (100 mg/ml) tissue in ice cold buffer containing 
50 mM Tris/HCl (pH 7.4), 100 mM KCl and 1mM EDTA. Thereafter skeletal muscle homogenates 
were centrifuged for 30 minutes at 4 ⁰C in an 8 x 50 ml rotor at 7741 g and skin at 27216 g for 10 
minutes at 4 °C using a Beckman Coulter J26-XPI centrifuge (USA). Supernatants were then 
transferred into Eppendorf tubes and frozen at -20 °C until further use. The protein concentration 
in supernatants was determined in skeletal muscle by the Biuret method (Gornall et al., 1949) and 
in skin by the Folin-Lowry method (Lowry et al., 1951), using Bovine serum albumin BSA as a 
standard. 
 
2.2.6.2 Tissue processing for Western blots 
 
Skeletal muscle and skin were processed by randomly selecting 3 samples from each group and 
homogenizing 100 mg tissue/ml in ice cold buffer containing 50 mM Tris, 1 mM EDTA, 1mM 
benzamidine, 1mM PMSF, 2 mM Na3VO4 and 0.5 µg/ml of aprotinin using an OMNI TH2 tissue 
homogenizer operated at 35000 rpm. Thereafter skin homogenates were centrifuged for 45 minutes 
at 4 ⁰C in an 8 x 50 ml rotor at 27000 g and skeletal muscle at 7741 g for 10 minutes using a 
Beckman Coulter J26-XPI centrifuge (USA). Supernatants were then transferred into eppendorf 
tubes and frozen at -20 ⁰C until further use. The protein concentration in supernatants was again 
determined in skeletal muscle by the Biuret method and in skin by the Folin-Lowry method using 
BSA as a standard. 
2.2.7 Enzyme assays 
2.2.7.1 Hexokinase activity assay 
 
Hexokinase activity  in skeletal muscle and skin samples was assayed as described by Ngubane et 




in a coupled reaction where glucose is phosphorylated using ATP as a phosphate donor to glucose-
6-phosphate in a reaction catalysed by hexokinase. The glucose-6-phosphate produced was 
converted to gluconate-6-phosphate while NADP+ is reduced to form NADPH. Hexokinase 
activity is directly proportional to NADPH produced. The rate of increase in absorbance due to 
NADPH is measured at 340 nm and 25°C for 8 minutes following 2 minutes of equilibration using 
a Varian Cary 50 UV/Vis Spectrophotometer (Australia).  
  
 
Figure 2. 3: Hexokinase activity assay 
The reaction mixture (2.8 ml) contained the following (final concentrations): 20 mM 
triethanolamine-HCl buffer (pH 7.6), 222 mM glucose, 8 mM MgCl2, 0.91 mM NADP
+, 0.64 mM 
ATP (Na salt), 5 mM mercaptoethanol, 0.55 U/ml Glucose-6-phosphate dehydrogenase. 100 µL 
of the sample was added to start the reaction. The activity was expressed as nmol/min/mg protein. 
2.2.7.2. Phosphofructokinase activity assay  
 
The activity of phosphofructokinase in skeletal muscle and skin was assayed according to methods 




phosphate was phosphorylated by phosphofructokinase to yield fructose-1,6-bisphosphate. The 
product is acted upon by aldolase to yield glyceraldehyde-3-phoshate which was further 
isomerized by triose phosphate isomerase into dihydroxyacetone phosphate. Dihydroxyacetone 
phosphate was catalyzed by glceraldehyde3-phosphate dehydrogenase while NADH was oxidized 
to NAD+. Phosphofructokinase activity was directly proportional to NADH consumed. The rate of 
decrease in absorbance by NADH was measured at 340 nm and 25 °C for 6 minutes following 2 


















The reaction mixture (1 ml) consisted of the following concentrations: 50 mM Tris (pH 8.0) 
containing 2 mM ATP, 5 mM MgCl2, 0.2 mM NADH, 2 mM Fructose-6-phosphate, 5U each of 
auxiliary enzymes (aldolase, triose phosphate isomerase, and α-glycerophosphate dehydrogenase). 
The reaction was started by addition of 30 µL of the sample. The activity was expressed as nmol/ 
min/ mg protein. 
 





2.2.7.3 Fructose-1, 6-bisphosphatase activity assay 
 
The activity of fructose-1,6-bisphosphatase in skeletal muscle and skin samples was measured in 
a coupled enzyme assay as described by Opie and Newsholme (1967) with modifications as 
illustrated in Figure 2.5. Fructose-1, 6-bisphosphate is dephosphorylated by fructose-1, 6-
bisphosphatase to yield fructose-6-phosphate. This product is isomerized by phosphoglucose 
isomerase to produce glucose-6-phosphate. The glucose-6-phosphate produced is converted to 
gluconate-6-phosphate by glucose-6-phosphate dehydrogenase while NADP+ is reduced to 
NADPH. Fructose-1, 6-bisphosphatase activity is directly proportional to NADPH produced. The 
rate of increase in absorbance due to NADPH was measured at 340 nm and 25 °C for 6 minutes 













The reaction medium consisted of the following in final concentrations: 50 mM-Tris-HCl buffer 
(pH 7.5), 20 mM mercaptoethanol, 6 mM MgSO4, 1 mM EDTA, 0.2 mM NADP
+ and 0.1 mM 




fructose-1, 6-diphosphate. To 640 µL of assay medium in a microcuvette, 550 U/mg protein each 
of glucose-6-phosphate dehydrogenase and phosphoglucose isomerase and 20 µL of tissue sample 
was added to start the reaction. The activity was expressed as nmol/ min/ mg protein. 
 
 
2.2.7.4 Glycogen phosphorylase activity 
 
Glycogen phosphorylase activity was assayed according to method described by Taylor et al. 
(2006). Samples (100 mg/ml) were homogenized in ice cold buffer containing 10 mM MOPS, 5 
mM EDTA, 50 mM NaF and 1m M DTT (pH7.0) using an OMNI TH2 tissue homogenizer 
operated at 35 000 rpm. The homogenates were then centrifuged at 9000 g for 10 minutes at 4 °C 
in a Beckman coulter J26-XPI centrifuge. 
The reaction was started by incubating a mixture of 50 µL of sample and 50 µL buffer containing 
33 mM MES, 0.34 mM glycogen, 22.3 mM Glucose-1-phosphate and 1µCi/ml radiolabeled 
D[U14C]-glucose-1-phosphate at 30°C for 20 minutes. Termination of the reaction was performed 
by adding 50 µL of reaction mixture onto a 2 x 2 cm filter paper then immediately submerging in 
70 % (v/v) ethanol to precipitate the glycogen. The filter paper was rinsed twice in ethanol for 30 
minutes then left to dry. The dried filter paper was then placed in scintillation vials containing 3 
ml FLUKA scintillation cocktail and the amount of 14C was determined using a PACKARD 1900 
TR liquid scintillation counter. Water was used as blanks to determine background counts. The 
activity was expressed as nmol/ min/ mg protein. 
 2.2.7.5 Glycogen synthase activity 
 
Glycogen synthase activity was assayed as described by Taylor et al. (2006) with modifications. 
50 mg/ml of tissue was homogenized in ice cold buffer containing 2 mM DTT, 20 mM EDTA, 20 
mM NaF and 50 mM potassium phosphate buffer using an OMNI TH tissue homogenizer operated 
at 35000 rpm. The homogenates were centrifuged at 20 000 g for 30 minutes at 4 °C using a 
Beckman coulter J26-XPI centrifuge. Supernatants were diluted (1:5) in buffer containing 50 mM 




The reaction was started by addition of 50 µL of sample to 50 µL buffer containing 50 mM Tris 
(pH 7.8), 25 mM NaF, 20 mM EDTA, 1% (w/v) glycogen, 1 µCi/ml [U14C] uridine diphosphate 
glucose, 5 mM Uridine diphosphate glucose and 10 mM glucose-6-phosphate. The reaction 
mixture was vortexed and incubated for 20 minutes at 30 °C. Termination of the reaction was 
performed by adding 50 µL of reaction mixture onto a 2 x 2 cm filter paper then immediately 
submerging in 70% (v/v) ethanol to precipitate the glycogen. The filter paper was rinsed twice in 
ethanol for 30 minutes then left to dry. The dried filter paper was then placed in scintillation vials 
containing 3 ml FLUKA scintillation cocktail and the amount of 14C was determined using a 
PACKARD 1900 TR liquid scintillation counter. Water was used as blanks to determine 
background counts. The activity was expressed as nmol/ min/ mg protein. 
2.2.8 Protein determination 
2.2.8.1 Folin- Lowry method 
Protein concentrations in skin were determined by the method of Lowry et al. (1951). The 
following reagents were prepared: sodium carbonate solution (20 g/L Na2CO3 in 0.1 M NaOH) 
and copper sulphate–sodium potassium tartarate solution (5 g/L CuSO4.5H2O in 10 g/L Na, K 
tatarate). On the day of the experiment alkaline reagent was prepared by mixing alkaline sodium 
carbonate solution and copper sulphate-sodium potassium tartrate solution 50:1 and the Folin 
Ciocalteu reagent was prepared by diluting stock 1:2 with deionized water. 
25 µL of sample and 475 µL of 0.1 N NaOH were added to each tube plus 5 ml of alkaline reagent. 
This solution was vortexed and incubated at 40˚C for 15 minutes. Samples were allowed to cool 
then add 0.5 ml Folin reagent was added to each tube. The solution was vortexed again and 
incubated at room temperature for 30 minutes and absorbance was read at 600 nm. Protein 
standards were prepared using BSA and these were used to construct a standard graph in the range 
20 - 100 µg. The concentration of each sample was extrapolated from the standard curve graph. 
 
2.2.8.2 Biuret assay method 
Protein concentrations were determined following methods described by Gornall et al. (1949) with 




(CuSO4.5H2O) and 9 g of sodium potassium tetrahydrate (KNaC4H4O4.H2O) in 500 ml of 0.2 M 
sodium hydroxide (NaOH). Thereafter 5 g of potassium iodide (KI) was added.  The volume was 
subsequently made up to 1 L by addition of 0.2 M NaOH.  
2 ml of diluted sample and 3 ml biuret reagent were added in each test tube. Afterwards the solution 
was vortexed and incubated at 37°C for 10 minutes. Thereafter samples were cooled and 
absorbance was read at 540 nm in a Varian Cary 50 UV/Vis Spectrophotometer. A standard curve 
using BSA was prepared by plotting absorbances of protein standards against their known protein 
concentrations in the range of 0-10 mg/ml. Protein concentrations in samples were calculated using 
this standard graph. 
2.2.9 Determination of glycogen content 
 
Glycogen content was determined following methods described by Nader and Esser (2001) with 
modifications. 0.5 g of tissue was boiled for 30 minutes in 1ml of 30% KOH saturated with NaSO4 
until completely digested. Thereafter glycogen was precipitated in 4 ml of ice cold 95% ethanol 
followed by centrifugation at 20000 g for 30 minutes. The pellet was then re-suspended in 1ml of 
deionised water. 1 ml of 5% Phenol was added to the glycogen suspension followed by 5 ml of 
sulphuric acid and incubation for 30 minutes in ice. Absorbance was read at 490 nm using an 
UVmini-1240, UV-VIS spectrophotometer. The standards were prepared using glycogen 
concentrations in the range of 0-100 µg/ml and water was used as a blank. The glycogen content 
in the samples were calculated using this standard graph. 
2.2.10 Histological studies 
 
Samples previously fixed in formalin were dehydrated in ascending concentrations (70%, 90% and 
100%) of ethanol and then in xylene. Thereafter tissues were positioned longitudinally and cross- 
sectionally and embedded in wax of paraffin overnight. Once tissues were embedded they were 
cut into 4µm sections using a microtome and placed in a 60°C water bath before being picked up 
in glass microscope slides. They were allowed to dry overnight. The slides containing sectioned 
tissues were then deparaffinised with xylene and rehydrated in decreasing concentrations (v/v) of 
ethanol (100%, 80%, 70% and 50% respectively) and finally rinsed in water. Slides were then 




3 minutes. The slides were then mounted with DPX, closed with a cover slip and left to dry for 2 
days. Slides were scanned using Leica SCN400, Germany (Software version: SlidePath Gateway 
Client viewer 2.0). 
 
2.2.11 Serum alanine amino transferase and aspartate amino transferase 
 
Blood samples were centrifuged at 3000 rpm for 10 minutes in a benchtop Labfuge 200 -
Heraeussepatech Centrifuge to obtain serum. Levels of serum alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) were determined using a Labmax Plano Chemistry analyser 
(Labtest Av, Paulo Ferreira do Costa, Brasilia, Brazil) 
2.2.12 SDS-PAGE and western blot analysis 
 
Proteins were resolved by SDS-PAGE using the SDS-PAGE (Laemmli) reducing buffer system 
(Laemmli, 1970). The following reagents were used to make 10% and 15% SDS PAGE gels: 
Acrylamide/Bis-acrylamide containing 29.2 g/100 ml of acrylamide and 0.8 g/100 ml of N’N’-bis-
methylene-acrylamide, 10% (w/v) SDS, 1.5 M Tris-HCl pH 8.8, 0.5 M Tris -HCl pH 6.8, running 
buffer, 10% (w/v) ammonium persulphate (APS) and sample buffer.  Stock solution of running 
buffer consisted of 30.3 g Tris-base, 144 g glycine and 10 g SDS pH 8.3 made up to 1 L with 
deionized water. The sample buffer (SDS reducing buffer) was made up of a total volume of 9.5 
ml composed of 3.55 ml deionized water, 1.25 ml of 0.5 M Tris -HCl, pH 6.8, 2.5 ml of glycerol, 
2 ml of 10% (w/v) SDS and 0.2 ml of 0.5% (w/v) bromophenol blue. 50 µL of mercaptoethanol 
was added to 950 µL sample buffer before use. The samples were diluted 1:2 with sample buffer 
and heated at 95°C for 4 minutes. 
To formulate 10% gels, 4.1 ml deionized water, 3.3 ml of 30% degassed acrylamide/bis-
acrylamide 2.5 ml gel buffer and 0.1 ml of 10% (w/v) SDS were mixed together. To prepare 15% 
gels the same ingredients were mixed together except 2.4 ml of deionized water and 5 ml of 
acrylamide/bis-acrylamide were used. In the resolving gel, 1.5 M Tris- HCl, pH 8.8 was used as 
gel buffer while in the stacking gels, 0.5 M Tris-HCl, pH 6.8 was used as the gel buffer. Before 




10% APS and 10 µL TEMED were added to the stacking gel. The buffers were swirled gently to 
initiate polymerization. 
Resolving gel was poured below comb teeth on glass of gel cassette with a layer of 1:1 butanol: 
water and allowed to polymerize for 45 to 60 minutes. Thereafter, the top of the resolving gel was 
rinsed and dried and stacking gel buffer was poured on top of resolving gel with desired comb to 
form wells. Stacking gel buffer was allowed to polymerize for 15-30 minutes. After the gel was 
formed, the comb was removed gently and wells were thoroughly rinsed with distilled water before 
use. 
Proteins of equal amounts and 3 µL of molecular weight marker were loaded into wells and 
resolved using a Bio-Rad mini PROTEIN 3 electrophoresis cell from BIORAD, South Africa. The 
samples and molecular weight marker were subjected to electrophoresis in running buffer at 110 
V for 90 minutes. The proteins on the gels were transferred to PVDF membranes in 
Tris/Glycine/Methanol buffer, pH 8.3 using a Bio-Rad Trans-Blot Electrophoretic Transfer Cell, 
(BIORAD, South Africa) and ran at 100 V for 2 hours. The PVDF was soaked in 100% methanol 
before transfer for activation of the membrane.  
After transferring, the membranes were blocked at 4 °C overnight in blocking buffer containing 
3% low fat milk in Tris-buffered saline with Tween 20 (TBS-Tween) to reduce protein non- 
specific binding. The TBS-Tween buffer was made up of 20 mM Tris, 500 mM NaCl, 0.05% 
Tween 20, pH 7.4. The primary antibody was added to blocking buffer (1:1000), overlaid on the 
PVDF membranes and shaken for 1 hour at room temperature. Membranes were then washed three 
times for 5 minutes with TBS-Tween buffer and probed with Goat anti-Rabbit IgG Alkaline 
phosphatase conjugate (diluted 1:1000 in PBST) for 1 hour at room temperature with gentle 
agitation. PVDF membrane was washed again with TBS-Tween for 5 minutes. Thereafter excess 
liquid was removed without letting the membrane dry and the immun-Star chemiluminescent 
substrate from BIORAD, (Johannesburg, South Africa) was added and incubated for 5 minutes. 
Thereafter signal was detected through chemiluminescence. The antibody-bound proteins were 
visualized using a Chemidoc imaging system, (BIORAD, South Africa). Images were captured 




2.2.13 Statistical analysis  
 
Data are expressed as means ± standard error of means (SEM). Statistical comparison of the 
differences between the control means and experimental groups was performed with GraphPad 
InStat Software (version 5.0, GraphPad Software, San Diego, California, USA), using one-way 





CHAPTER 3  
Results 
 
This chapter represents the results of experiments performed to evaluate the effects of oleanolic 
acid and Centella asiatica on selected glycolytic and gluconeogenic enzymes in skeletal muscle 
and skin diabetic rats by determining enzyme activity and enzyme expression. The activities and 
expression of key enzymes of glycogen metabolism as well as results of histological examination 
of skeletal muscle and skin of non-diabetic, diabetic and treated animals are also reported. 
3.1 Enzyme activity in tissues of non-diabetic and diabetic animals treated with OA 
 
Figures 3.1 to 3.4show the effect of OA on the activities of hexokinase, phosphofructokinase and 










Figure 3.1: Effects of OA on hexokinase activity in skeletal muscle of non-diabetic and diabetic rats 
following 14 days of treatment. Values are expressed as means and vertical bars indicate SEM, (n = 
6). HK = hexokinase; NC = Non-diabetic control; NO = Non-diabetic + OA; DC = Diabetic control; 






















































Figure 3.1 depicts the effects of OA on hexokinase activity in skeletal muscle of non-diabetic and 
diabetic rats. At the end of the 14-day treatment study, there were no significant differences in 
hexokinase activity amongst the control groups and within non-diabetic and diabetic animal 
groups. However, amongst the non-diabetic animals, treatment with OA increased hexokinase 
activity by 75% compared to the control animals. Hexokinase activity slightly decreased in diabetic 
control animals by comparison to non-diabetic control animals. Amongst the diabetic animals, 
treatment with OA increased hexokinase activity while treatment with metformin did not alter the 













Figure 3.2: Effects of OA on (A) phosphofructokinase and (B) fructose-1,6-bisphosphatase activity in 
skeletal muscle of non-diabetic and diabetic rats following 14 days of treatment. Values are expressed 
as means and vertical bars indicate SEM, (n = 6). # = p < 0.05 by comparison with NC and * = p < 
0.05 by comparison with DC. PFK = phosphofructokinase; FBPase = fructose-1,6-bisphosphatase; 
NC = Non-diabetic control; NO = Non-diabetic + OA; DC = Diabetic control; DO = Diabetic + OA 

















































































































The results in Figure 3.2 show the effect of OA on (A) phosphofructokinase and (B) fructose-1, 6-
bisphosphatse activities in skeletal muscle after 14 days of treatment. Non-diabetic OA treated 
animals did not show significant difference in phosphofructokinase activity compared to non-
diabetic control animals. However, phosphofructokinase activity significantly (p < 0.05) decreased 
by 77% in diabetic animals compared to non-diabetic control animals after the 14-day treatment 
period. Diabetic animals treated with OA showed significantly (p < 0.05) increased (432 %) 
activity compared to the diabetic control animals. Animals treated with metformin also showed 
higher phosphofructokinase activity than diabetic controls although this was not statistically 
significant. 
There were no significant differences in fructose-1, 6- bisphosphatase activity between non-
diabetic control and diabetic control animals and within non-diabetic and diabetic treatment 
groups. However, fructose-1, 6-bisphosphatase activity increased in diabetic control animals by 
25% compared to untreated control animals. Treatment of diabetic animals with OA resulted in no 
significant difference compared to the diabetic control animals. Diabetic animals treated with 
metformin had slightly lower enzyme activity compared to the diabetic control although this 



















Figure 3.3: Effects of OA on hexokinase activity in skin of non-diabetic and diabetic rats after 14 days 
of treatment. Values are expressed as means and vertical bars indicate SEM, (n = 6). HK = 
hexokinase; NC = Non-diabetic control; NO = Non-diabetic + OA; DC = Diabetic control; DO = 
Diabetic + OA and DM = Diabetic + Metformin. 
The results in Figure 3.3 depicts the effects of OA on hexokinase activity in skin after a 14-day 
study period. Hexokinase activity in non-diabetic animals treated with OA was reduced compared 
to the non-diabetic control animals. The diabetic controls showed higher hexokinase activity than 
non-diabetic control animals although this was not significantly different. Diabetic animals treated 
with OA had slightly increased activity compared to the diabetic control animals. Treatment of 
diabetic animals with metformin resulted in lower hexokinase activity by 22% compared to 






























































Figure 3.4: Effects of OA on (A) phosphofructokinase and (B) fructose-1, 6-bisphosphatase activity 
in skin of non-diabetic and diabetic rats after 14 days of treatment. Values are expressed as means 
and vertical bars indicate SEM, (n = 6). PFK= phosphofructokinase; FBPase = fructose-1,6-
bisphosphatase; NC = Non-diabetic control; NO = Non-diabetic + OA; DC = Diabetic control; DO = 
Diabetic + OA and DM = Diabetic + Metformin. 
Figure 3.4 represents the effects of OA on (A) phosphofructokinase and (B) fructose-1, 6-
bisphosphatase activity in skin of non-diabetic and diabetic animals after 14 days of treatment. 
Amongst the non-diabetic animals, OA treated animals showed 22% lower phosphofructokinase 
activity compared to the controls although this was not statistically significant (p > 0.05). Diabetic 
control animals also demonstrated low phosphofructokinase activity compared to the non-diabetic 
control animals. OA treated diabetic animals had increased phosphofructokinase activity by 71% 
while metformin treated diabetic animals showed no significant differences in activity compared 
to diabetic control animals. 
Amongst the non-diabetic animals, those treated with OA had lower fructose-1,6-bisphosphatase 






























































































non-diabetic control and diabetic control animals showed no significant difference in their enzyme 
activities, the enzyme activity was lower in diabetic animals. Treatment of diabetic animals with 
OA and metformin slightly lowered enzyme activity although not significantly. 
 
Table 3.1: Effects of OA of glycogen levels in skeletal muscle and skin after 14 days of 
treatment of non-diabetic and diabetic animals. 
Treatment groups Muscle (mg/g tissue) Skin (mg/g tissue) 
NC 0.54 ± 0.05 0.75 ± 0.07 
NO 1.2 ± 0.07# 0.73 ± 0.10 
DC 0.63 ± 0.01 0.75 ± 0.09 
DO 0.89 ± 0.01* 0.64 ± 0.04 
DM 0.67 ± 0.05 0.81 ± 0.10 
Values are expressed as means ± SEM, (n=6 in each group). # = p < 0.05 by comparison with NC and 
* = p < 0.05 by comparison with DC. NC = Non-diabetic control; NO = Non-diabetic + OA; DC = 
Diabetic control; DO = Diabetic + OA and DM = Diabetic + Metformin. 
Table 3.1 depicts the effects of OA on glycogen levels in muscle and skin after 14 days of 
treatment. In muscle, the amount of glycogen was 122% higher non-diabetic animals treated with 
OA compared to the non-diabetic control animals, this increase being significant (p < 0.05). This 
NO group had the highest amount of glycogen amongst all the groups. Diabetic animals treated 
with OA and metformin had higher glycogen levels compared to diabetic controls with those 
treated with OA being 41% higher (p < 0.05).  
In skin, there were no significant differences in glycogen levels amongst the groups. OA treated 
non-diabetic animals had slightly lower glycogen levels than the non-diabetic control animals. 
Diabetic animals treated with OA had a lower amount of glycogen while those treated with 




treated OA had the lowest amount of glycogen while those treated with metformin had the highest 
amount of glycogen. 














Figure 3.5: Effects of CA on skeletal muscle hexokinase activity in of non-diabetic and diabetic 
animals after 14 days of treatment. Values are expressed as means and vertical bars indicate SEM, 
(n = 6). HK = hexokinase; NC = Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA 
(500 mg/kg b.w.); D+1000 = Diabetic + CA (1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
  
The results of effects of CA on hexokinase activity in skeletal muscle following 14 days of 
treatment are shown in Figure 3.5. There were no statistical differences in hexokinase activity 
amongst all treatment groups. However, diabetic control animals showed somewhat lower activity 
than non-diabetic untreated animals. Diabetic animals treated with 500 mg/kg b.w. of CA showed 
an increase in enzyme activity when compared to the diabetic controls. This activity was slightly 





























































Figure 3.6: Effects of CA on skeletal muscle (A) phosphofructokinase and (B) fructose-1, 6-
bisphosphatase activity of non-diabetic and diabetic rats after 14 days of treatment. Values are 
expressed as means and vertical bars indicate SEM, (n = 6). # = p < 0.05 by comparison with NC and 
* = p < 0.05 by comparison with DC. PFK = phosphofructokinase; FBPase = fructose-1,6-
bisphosphatase; NC = Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA (500 
mg/kg b.w.); D+1000 = Diabetic + CA (1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
Figure 3.6 depicts the effects of CA on skeletal muscle (A) phosphofructokinase and (B) fructose-
1, 6- bisphosphatase activity following 14 days of treatment. Diabetic animals had reduced (p < 
0.05) the activity of phosphofructokinase by 90% compared to non-diabetic animals. Diabetic 
animals treated with 500 and 1000 mg/kg b.w of CA extract had increased (p < 0.05) 
phosphofructokinase activity amounting to 624% and 278% respectively compared to diabetic 
control animals. Treatment of diabetic animals with metformin also resulted in an increase 
phosphofructokinase activity compared to control animals. 
Diabetic control animals had lower fructose-1, 6-bisphosphatase activity compared to non-diabetic 
control animals. Treatment of diabetic animals with 500 mg/kg b.w of CA resulted in a 98% 






















































































































treated with 1000 mg/kg b.w of CA and those treated with metformin showed no significant 













Figure 3.7: Effects of CA on hexokinase activity in skin of non-diabetic and diabetic animals after 14 
days of treatment. Values are expressed as means and vertical bars indicate SEM, (n = 6). * = p < 
0.05 by comparison with DC. HK = hexokinase; NC = Non-diabetic control; DC = Diabetic control; 
D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 = Diabetic + CA (1000 mg/kg b.w.) and DM = 
Diabetic + Metformin. 
The results of effects of CA on hexokinase activity in skin following 14 days of treatment are 
shown in Figure 3.7. Diabetic control animals showed lower hexokinase activity than non-diabetic 
control animals. Amongst the diabetic animals, those treated with 500 mg/kg b.w. of CA showed 
higher activity than the control animals although this was not statistically significant (p > 0.05). 
Diabetic animals treated with 1000 mg/kg b.w. of CA had 53% lower hexokinase activity than 
diabetic control animals, this difference being significant (p < 0.05). Metformin treated diabetic 
animals also had lower enzyme activity than the diabetic controls, although this was not 


































































Figure 3.8: Effects of CA of (A) phosphofructokinase (PFK) and (B) fructose-1, 6-bisphosphatase 
(FBPase) activity in skin of non-diabetic and diabetic rats after 14 days of treatment. Values are 
expressed as means and vertical bars indicate SEM, (n = 6). # = p < 0.05 by comparison with NC. NC 
= Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 = 
Diabetic + CA (1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
Figure 3.8 depicts the effects of CA on (A) phosphofructokinase and (B) fructose-1,6-
bisphosphatase activity following 14 days of treatment. Phosphofructokinase activity in diabetic 
control animals was 75% lower compared to non-diabetic control animals, this decrease being 
significant (p < 0.05). Treatment of diabetic animals with 500 and 1000 mg/kg b.w. of CA 
increased activity of the enzyme compared to the diabetic control animals. Treatment of diabetic 
animals with metformin significantly lowered (p > 0.05) phosphofructokinase activity by 55% 
compared to the diabetic control animals. 
The fructose-1,6-bisphosphatase activity of the diabetic control animals was lower than that of the 
non-diabetic control animals. Amongst the diabetic animals, treatment with 500 mg/kg b.w. of CA 







































































































treated with 1000 mg/kg b.w. of CA extract had slightly decreased enzyme activity compared to 













Figure 3.9: Effects of CA on glycogen synthase (GS) activity in skin of non-diabetic and diabetic 
animals after 14 days of treatment. Values are expressed as means and vertical bars indicate SEM, 
(n = 6). * = p < 0.05 by comparison with DC. NC = Non-diabetic control; DC = Diabetic control; 
D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 = Diabetic + CA (1000 mg/kg b.w.) and DM = 
Diabetic + Metformin. 
 
The effects of CA on glycogen synthase activity in skin is depicted in Figure 3.9. Non-diabetic 
and diabetic control animals had similar enzyme activity. Diabetic animals treated with 500 mg/kg 
b.w. of CA showed a dramatic 346% higher (p < 0.05) enzyme activity than the diabetic control 
animals. Diabetic animals treated with 1000 mg/kg b.w. and those treated with metformin also had 
higher glycogen synthase activity compared to the diabetic control animals but the increases were 






























































Figure 3. 10: Effects of CA on glycogen phosphorylase (GP) activity in skin of non-diabetic and 
diabetic animals after 14 days of treatment. Values are expressed as means and vertical bars indicate 
SEM (n = 6). * = p < 0.05 by comparison with DC. NC = Non-diabetic control; DC = Diabetic control; 
D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 = Diabetic + CA (1000 mg/kg b.w.) and DM = 
Diabetic + Metformin. 
 
The effects of CA on glycogen phosphorylase activity in skin is shown in figure 3.10. There were 
no statistical differences amongst all the treatment groups. However, diabetic control animals 
showed lower GP activity than non-diabetic control animals. Amongst the diabetic animals, those 
treated with 500 mg/kg b.w. of CA, 1000 mg/kg b.w. of CA and metformin showed elevated 
enzyme activity compared to the diabetic control animals. The 500 mg/kg b.w. of CA restored GP 



















































Table 3.2: Effects of CA on glycogen levels in skin after 14 days of treatment. 
Treatment 
groups 
NC DC D+500 D+1000 DM 
Skin (mg/g) 
tissue 
0.74 ± 0.06 0.85 ± 0.05 0.80 ± 0.06 0.76 ± 0.05 0.80 ± 0.061 
Values are expressed as mean ± SEM, (n = 6). NC = Non-diabetic control; DC = Diabetic control; 
D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 = Diabetic + CA (1000 mg/kg b.w.) and DM = 
Diabetic + Metformin. 
 
Table 3.2 shows the effects of CA on glycogen levels in skin of non-diabetic and diabetic animals 
following 14 days of treatment. There were no statistically different values in glycogen in levels 
amongst the groups (p > 0.05). Diabetic control animals presented 15% higher amounts of 
glycogen compared to the non-diabetic control animals. Amongst the diabetic animals, those 
treated 500 mg/kg b.w. of CA, 1000 mg/kg b.w. of CA and metformin showed 6 and 11% lower 
glycogen levels than control animals, respectively. Animals treated with 1000 mg/kg b.w. of CA 
had the lowest amount of glycogen content compared to diabetic control animals and the animals 
treated with 500 mg/kg b.w. of CA. Metformin treated animals had almost the same amount of 









Table 3.3: Effects of CA on serum aspartate aminotransferase (AST) and alanine amino 
transferase (ALT) following 14 days of treatment. 
Values are expressed as mean ± SEM, (n = 6). * = p < 0.05 by comparison with DC. NC = Non-diabetic 
control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 = Diabetic + CA 
(1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
 
Table 3.3 shows the effects of CA on serum enzymes, aspartate aminotransferase and alanine 
amino transferase, in non-diabetic and diabetic rats following 14 days of treatment. The diabetic 
control animals showed higher AST activity than that of the normal animals. The diabetic animals 
treated with 500 mg/kg b.w of CA, 1000 mg/kg b.w. of CA and metformin had lower AST 
activities compared with the diabetic control animals. Both groups treated with CA had almost 
very similar activities of AST 
With respect to ALT, the diabetic control animals had a higher activity of ALT enzyme than the 
non-diabetic control animals. Diabetic animals treated with 500 mg/kg b.w. of CA had 
significantly lower (p < 0.05) activity of ALT compared to the diabetic control animals. Diabetic 






NC DC D+500 D+1000 DM 
AST (U/L) 49.17 ± 2.33 57.83 ± 3.08 47.83 ± 4.28 47.00 ± 1.65 49.50 ± 1.78 




3.3 SDS-PAGE of muscle and skin proteins  
 
SDS-PAGE gels were run using 10% reducing polyacrylamide gels for skeletal muscle and skin 
to show their distribution pattern in each of the treatment groups. Figure 3.11 represents results of 
proteins of those animals treated with OA while Figure 3.12 represents results of animals treated 















Figure 3. 11: 10% reducing SDS-PAGE gel of (A) skeletal muscle and (B) skin tissue homogenates in 
the OA study. 40 µg of protein were loaded in each lane. MW= Molecular Weight; NC = Non-diabetic 
control; NO = Non-diabetic + OA; DC = Diabetic control; DO = Diabetic + OA and DM = Diabetic + 
Metformin. 
The results in Figure 3.11 shows 10% reducing SDS-PAGE gels of skeletal muscle and skin 
showing the distribution of proteins between the different treatment groups after gels were stained 
with Coomassie Blue. In muscle, NC group appeared to show highest intensity of proteins 





compared to the rest of the treatment groups. There was also a high intensity of protein around 37 














Figure 3.12: 10% reducing SDS-PAGE gel of skeletal muscle (A) and skin (B) tissue homogenates in 
the CA study.40 µg of protein was loaded in each lane. MW= Molecular Weight; NC = Non-diabetic 
control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 = Diabetic + CA 
(1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
Figure 3.12 shows 10% reducing SDS-PAGE gels indicating protein distribution in skeletal muscle 
and skin tissue homogenates stained with coomassie blue stain. Muscle tissue homogenates 
seemed to show a higher amount of protein than skin. In muscle, the proteins appeared most intense 
around 37 kDa. In skin proteins appeared more intense above 25 kDa, below 50 kDa and below 
75 kDa.  






















































3.4 Enzyme expression studies in muscle and skin 
For good resolution, 10% reducing polyacrylamide gels were used for expression of PFK and GP 
while 15% reducing polyacrylamide gels were used for expression of GAPDH in both skeletal 
muscle and skin. 
3.4.1 Expression of PFK and GP proteins in muscle and skin. 











Figure 3. 13: (A) Western blots of PFK (85 kDa) and GAPDH (37 kDa) in skeletal muscle following 
14 days of treatment with OA. 20 and 40 µg was loaded for PFK and GAPDH respectively. (B) PFK 
was normalized against GAPDH and were expressed as PFK/GAPDH ratio. MW= Molecular 
Weight; NC = Non-diabetic control; NO = Non-diabetic + OA; DC = Diabetic control; DO = Diabetic 
+OA and DM = Diabetic + Metformin. 
 
The results of the effects of OA on expression of PFK and GAPDH in muscle are shown in Figure 
3.13. Amongst the non-diabetic animals, control and OA-treated animals with showed almost 
similar amounts of expression of PFK. The diabetic control animals expressed a higher level of 






















































was highest in OA treated animals than in the control animals. Diabetic control metformin treated 













Figure 3.14: (A) Western blots of PFK (85 kDa) and (B) GAPDH (37 kDa) in skin following 14 days 
of treatment with OA. 30 and 40 µg was loaded for PFK and GAPDH respectively. PFK was 
normalized against GAPDH and were expressed as PFK/GAPDH ratio. MW = Molecular Weight; 
NC = Non-diabetic control; NO = Non-diabetic + OA; DC = Diabetic control; DO = Diabetic + OA 
and DM = Diabetic + Metformin. 
 
The results of the effects of OA on expression of PFK and GAPDH in skin are shown in Figure 
3.14. Non-diabetic animals treated with OA had a slightly higher amount of expression ratio than 
the control animals. The diabetic control animals had 3-fold higher expression of PFK compared 
non-diabetic control animals. Amongst the diabetic animals, treatment with OA and metformin 
reduced PFK expression by 27% and 60%, respectively compared to diabetic control animals. The 


































































Figure 3. 15: (A) Western blots of PFK (85 kDa) and GAPDH (37 kDa) in muscle following 14 days 
of treatment with CA. 30 µg and 40 µg was loaded for PFK and GAPDH respectively. (B) PFK was 
normalized against GAPDH and were expressed as a PFK/GAPDH ratio. MW = Molecular Weight; 
NC = Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 
= Diabetic + CA (1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
 
The effects of CA in expression of PFK in muscle is depicted in Figure 3.15. Diabetic control 
animals showed higher PFK expression than the non-diabetic control animals. Diabetic animals 
treated with 500 mg/kg b.w. and 1000 mg/kg b.w. of CA had lower PFK expression compared to 
the diabetic control animals with those treated with 1000 mg/kg b.w. having the lowest. Diabetic 
animals treated with metformin had higher expression compared to the diabetic control animals. 
Diabetic animals treated with metformin showed the highest amount of expression in muscle. 
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Figure 3.16: (A) Western blots of PFK (85 kDa) and GAPDH (37 kDa) in skin following 14 days of 
treatment with CA. 30 µg and 40 µg was loaded for PFK and GAPDH respectively. (B) PFK was 
normalized against GAPDH and were expressed as a PFK/GAPDH ratio MW= Molecular Weight; 
NC = Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 
= Diabetic + CA (1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
 
The effects of CA on PFK expression in skin of non-diabetic and diabetic animals are shown in 
Figure 3.16. Diabetic control animals showed a higher PFK expression than the non-diabetic 
control animals. Diabetic animals treated with 500 mg/kg b.w. of CA had decreased enzyme 
expression levels than the diabetic control animals. Treatment of diabetic animals with 1000 mg/kg 
b.w. of CA resulted in the highest expression of PFK among the diabetic animals. Diabetic animals 

















































































Figure 3.17: (A) Western blots of GP (97 kDa) and GAPDH (37 kDa) in skin following 14 days of 
treatment with CA. 30 µg and 40 µg were loaded for PFK and GAPDH respectively. (B) PFK was 
normalized against GAPDH and were expressed as a PFK/GAPDH ratio. MW = Molecular Weight; 
NC = Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 
= Diabetic + CA (1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
 
The effects of CA on glycogen phosphorylase (GP) expression in skin are shown in Figure 3.17. 
Diabetic control animals had higher GP expression levels than the non-diabetic control animals. 
Treatment of diabetic animals with 500 mg/kg b.w. of CA lowered the GP expression compared 
to the diabetic controls. Diabetic groups treated with 1000 mg/kg b.w. of CA and with metformin 
showed higher levels of GP expression compared to the diabetic control animals. 





























































3.5 Histological examinations 
 
The following are morphological and statistical observations of hematoxylin an eosin (H and E) 



















Figure 3.18: H and E stains of longitudinally arranged skeletal muscle fibres with peripherally 
located multi nuclei. NC = Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA (500 
mg/kg b.w.); D+1000 = Diabetic + CA (1000 mg/kg b.w) and DM = Diabetic + Metformin. 













Figure 3.18 illustrates H and E stain of longitudinally cut skeletal muscle fibres that run parallel to 
each other enclosed by an endomysium. In non- diabetic controls, each muscle fibre has striations 
running perpendicular to the muscle fibre length and oval shaped peripherally located multinuclei. 
Skeletal muscle fibres of a diabetic control animal with peripherally located multinuclei showed 
discontinuity between muscle fibres, apparent decrease in fibre thickness and an increase in spaces 
containing connective tissue compared to the non-diabetic control animals. Diabetic animals 
treated with 500 mg/kg b.w. of CA show skeletal muscle fibres that appear close with little space 
between the fibres and damage to fibres appear less compared diabetic control animals. The muscle 
fibres also appear continuous with less breakage between the fibres. Diabetic animals treated with 
1000 mg/kg b.w. of CA appear to have thin but continuous and closely spaced muscle fibres with 
peripherally located nuclei compared to diabetic control animals. There was also an apparent 
increase in spaces that encompass connective tissue and within fibres. Muscle fibres of diabetic 
animals treated with metformin appear continuous, but there was a slight increase in the spaces 














Table 3.4: Morphometric data of longitudinal and cross sections of skeletal muscle in normal 
and diabetic rats. 
Values are expressed as mean ± SEM, (n = 3). * = p < 0.05 by comparison with DC. NC = Non-diabetic 
control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 = Diabetic + CA 
(1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
 
The muscle fibre thickness of longitudinal sections and muscle fibre diameter of cross sections of 
non-diabetic and diabetic animals are shown in table 3.4 above. Muscle fibre thickness in diabetic 
animals had lower mean muscle fibre thickness than that of non-diabetic animals although the 
changes were not statistically significant (p > 0.05). There was a significant (p < 0.05) 44% and 
24% increase in muscle fibre thickness of both D+500 and D+1000 respectively compared to the 
diabetic control animals. There were no significant changes in muscle fibre diameter of other 
groups compared to the diabetic control animals. 
  
 Longitudinal sections Cross sections 
Treatment groups Muscle fibre thickness (µm) Muscle fibre diameter (µm) 
NC 38.85 ± 2.2 53.87 ± 0.52 
DC 32.68 ± 0.54 48.33 ± 1.17 
D+500 46.98 ± 2.01* 53.21 ± 0.46 
D+1000 40.23 ± 0.88* 53.42 ± 1.25 


















Figure 3.19: H and E stains of cross section skeletal muscle fibres with peripherally located multi 
nuclei. NC = Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); 
D+1000 = Diabetic + CA (1000 mg/kg b.w.) and DM = Diabetic + Metformin. (Magnification = 36 X 
50 µm). 
Figure 3.19 illustrates hematoxylin and eosin section of cross-sectionally cut skeletal muscle fibre 
with peripherally located multinuclei enclosed by an endomysium. The polygonal shaped muscle 
fibres appear irregularly shaped in diabetic control animals compared to non-diabetic control 
animals. There also appeared to be more spaces between the muscle fibres in diabetic animals and 







D+1000 and DM) appear to have more regularly shaped muscle fibres and less connective tissue 
between the fibres compared to the diabetic control animals. 
 
Table 3.5: Morphometric data of cross sections of skin epidermal thickness in non-diabetic and 
diabetic rats. 
Treatment groups Granular thickness (µm) 
Spinous and basal thickness 
(µm) 
NC 16.30 ± 087 23.31 ±1.76 
DC 12.33 ± 0.86 20.15 ±1.67 
D+500 20.24 ±1.99* 24.31 ±1.02 
D+1000 17.82 ±1.44 20.48 ±1.08 
DM 15.94 ±1.93 22.15 ±3.15 
Values are expresses as mean ± SEM (n =3 in each group). * = p < 0.05 by comparison with DC. NC 
= Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); D+1000 = 
Diabetic + CA (1000 mg/kg b.w.) and DM = Diabetic + Metformin. 
 
The morphometric data of cross-sectionally cut skin epidermis of non-diabetic and diabetic rats 
are shown in Table 3.5. The keratin layer was not measured due to its free-flowing nature which 
made it hard to accurately gauge. The Spinous and basal layer were difficult to differentiate 
between beginning and end without compromising the results; therefore, they were measured 
together. Both the granular, spinous and basal length were shorter in diabetic control animals 
compared to the normal control animals. Diabetic animals treated with CA showed an increase 
granular length with those treated with 500 mg/kg b.w. of CA being 64% higher. Diabetic animals 
treated with metformin also showed an in increase in granular length. 
The spinous and basal layers were thinner in diabetic control animals than in the non-diabetic 




thicker spinous and basal layers compared to the diabetic control animals. These differences 

















Figure 3.20 H and E stain skin longitudinal- section skin epithelium of non-diabetic and diabetic 
animals. K = keratin layer; G = granular layer; S= spinous layer; B = basal layer and C = connective 
tissue; NC = Non-diabetic control; DC = Diabetic control; D+500 = Diabetic + CA (500 mg/kg b.w.); 





















Longitudinal-sections of skin epithelium and connective tissue of normal and diabetic animals are 
shown in Figure 3.20. The skin is mainly made up of epidermis and dermis. Structural 
characteristics of skin include 4 distinct layers in epidermis and connective tissue in dermal layer. 
The 4 layers include, keratin, granular, spinous and basal layer. The basal layer rests on basement 
membrane and is formed by round columnar cells while spinous layer is formed of polyhedral 
cells. The granular layer is formed by basophilic granules that appear deeply stained and keratin 
layer is made up of flat keratin cells with no nuclei. Diabetic animals appear to have a thinner 
epidermis and less connective tissue compared to non-diabetic animals. Note the granular layer is 
reduced and basal cells appear deeply stained. Amongst the diabetic animals, treatment with both 
concentrations of CA and metformin resulted in visible increase in epithelial thickness, granular 
cells and increase in the amount of connective tissue. The number of keratinized cells also appear 




















The aim of this study was to investigate the effects of oleanolic acid and methanol extract of 
Centella asiatica leaves on selected enzymes of glucose metabolism in muscle and skin of 
streptozotocin-induced diabetic male Sprague-Dawley rats; and to analyze the histological changes 
occurring in these tissues. The study also investigated changes in serum marker enzymes of tissue 
damage. This study was conducted to assess how OA and CA achieve their hypoglycaemic 
potential in a type-II insulin insufficiency diabetic model and insulin insufficiency and insulin 
resistance Type-II diabetic model respectively. Diabetes was induced using 40 mg/ kg b.w. of 
streptozotocin (STZ). STZ is a cytotoxic glucose analog that mimics the effects of diabetes when 
administered to animals. Development of hyperglycaemia in animal models induced with 
streptozotocin is mainly due to the destruction of pancreatic β-cells via uptake by the GLUT-2 
transporter (Szkudelski, 2001). STZ also increases reactive oxygen species formation and nitric 
oxide production contributing towards DNA damage (Lenzen, 2008). This causes DNA alkylation 
followed by the activation of poly ADP ribose polymerase (PARP) leading to the reduction of 
NAD+ and ATP followed by inhibition insulin production (Szkudelski, 2001; Lenzen, 2008; 
Ventura-Sobrevilla et al., 2011). Chronic hyperglycaemia can result in glucose-induced insulin 
resistance, particularly in skeletal muscle. Hyperglycaemia also impairs glucose metabolism, 
predominantly in rate-limiting enzymes involved in glycolysis, gluconeogenesis, glycogenesis, 
and glycogenolysis. Theses enzymes include hexokinase, phosphofructokinase, fructose-1,6-
bisphosphatase glycogen synthase and glycogen phosphorylase. 
Effects of OA treatment in diabetic animals  
 
This study investigated the effects of OA on enzymes of glucose metabolism in both muscle and 
skin using an insulin insufficiency type-II diabetes model. Metformin was used as a positive 
control as it is used to manage type-II diabetes. Deployment of OA was to investigate whether OA 
had any activity that enhances insulin action in a type-II diabetic animal model in vivo, as it does 




at higher doses that induce type I diabetes to its effect at current lower doses that induce insulin 
insufficiency type-II diabetes (Mukundwa et al., 2016a; Mukundwa et al., 2016b). 
Skeletal muscle is responsible for 75% of insulin stimulated glucose disposal (Saltiel and Kahn, 
2001). Glucose uptake and subsequent phosphorylation in skeletal muscle occurs via of GLUT4 
transporters and hexokinase, respectively (Dimitriadis et al., 2011). Hexokinase is the first rate 
limiting enzyme of glycolysis that catalyzes the phosphorylation of glucose to glucose-6-
phosphate trapping glucose in the cells. The second rate limiting enzyme in glycolysis, 
phosphofructokinase catalyzes the phosphorylation of fructose-6-phosphate yielding fructose-1,6- 
bisphosphate. These are essential in glucose regulation and are linked to complete glycolysis 
regulation. This study investigated the effects OA on glycolytic enzymes hexokinase and 
phosphofructokinase in skeletal muscle of diabetic and non-diabetic rats following a 14-day 
treatment period. The results in Figure 3.1 and 3.2A showed that hexokinase and 
phosphofructokinase had 19% and 77% decrease in activity, respectively in diabetic animals 
compared to the non-diabetic animals. A similar decrease in activities in these enzymes in muscle 
has been observed in previous studies (Da Silva et al., 2010; Rasineni et al., 2010). In this study, 
treatment of diabetic animals with OA ameliorated this decrease in enzyme activity by increasing 
hexokinase and phosphofructokinase activity by 82% and 432% respectively. This suggests that 
OA possibly increases activities of hexokinase and phosphofructokinase through enhancing insulin 
secretion from β-cells, enhancing the effects of insulin or promoting direct activation of 
hexokinase and phosphofructokinase leading to subsequent stimulation in rate of glycolysis. It has 
been previously suggested that OA may enhance insulin secretion in vitro (Teodoro et al., 2008). 
Expression of PFK in skeletal muscle is said to be influenced by genetic variation and insulin 
sensitivity (Keildson et al., 2014). PFKM encodes for the enzyme PFK in muscle. Changes in gene 
expression can affect the phenotype of expressed gene therefore affect the regulatory effect of that 
protein. Mutation of this gene has been shown to cause glycogen storage diseases. Findings of this 
study indicate that the expression of PFK was slightly increased in diabetic animals compared to 
non-diabetic animals in skeletal muscle. The same phenomenon of overexpression of PFK 
phenomenon was seen in a previous study (Keildson et al., 2014). Keildson et al. (2014) suggested 
that the increase in PFK expression might be an attempt to overcome inhibition of PFK activity. 
Treatment of diabetic rats with OA further increases PFK expression. In rat skin, however (Figure 




animals after treatment with OA. This suggests that the effect of OA on expression may vary 
depending on the target tissue. 
This study also investigated the effects of OA on gluconeogenic enzyme fructose-1,6-
bisphosphatase in skeletal muscle following a 14-day treatment regimen. Fructose-1,6-
bisphosphatase catalyzes the hydrolysis of fructose-1, 6-phosphate yielding fructose-6-phosphate 
and an inorganic phosphate. FBPase plays a role in overall regulation of gluconeogenesis and is 
considered a potential target for diabetes treatment (Erion et al., 2005). FBPase activity is 
increased in diabetic animals due to insulin insufficiency. The results in Figure 3.2B show that 
FBPase activity is increased by 25% in diabetic animals compared to the non-diabetic animals. A 
similar increase in FBPase activity was seen in liver, kidney and skeletal muscle of alloxan induced 
type-II diabetic model (Alam et al., 2014). Treatment of diabetic rats with OA did not affect 
FBPase activity compared to the diabetic control animals. This may be because OA requires a 
threshold amount of FBPase to exert its effects in skeletal muscle. Since skeletal muscle is not a 
gluconeogenic tissue it produces less amount of FBPase compared to gluconeogenic tissues such 
as liver and kidney (Mizunuma and Tashima, 1986). 
The skin makes up 15% of a person’s total body weight and reduced glucose uptake in skin cells 
could contribute towards higher blood glucose levels in diabetes (Spravchikov et al., 2001). In our 
previous study, where a type-I diabetic model was used, hexokinase activity was reduced but not 
significantly in diabetic animals (Mukundwa et al., 2016a). In this study hexokinase activity in 
skin was only slightly increased by 8% in diabetic animals compared to non-diabetic control 
animals (Figure 3.3). Thus, diabetes does not seem to cause major change in skin hexokinase 
activity. This could be attributed towards the fact that during diabetes, glucose breakdown for 
energy production may be channeled towards major glycolytic tissues such as liver, kidneys and 
skeletal muscle. This may be the reason for increased dermatologic complications observed in 
diabetic patients causing poor wound healing properties and reduced collagen formation 
(Bermudez et al., 2011; Knas et al., 2013). Diabetic animals treated with OA showed increased 
hexokinase activity compared to the control animals. OA possibly increases hexokinase activity 
by enhancing insulin secretion from β-cells (Teodoro et al., 2008). 
Skin contains rapidly dividing cells that have high rates of proliferation and therefore has a high 




glycolysis and PFK enzyme activity has been shown to exist in skin samples (Kondo and Adachi, 
1971). The results in Figure 3.4A show that diabetic animals had a 74% decrease in PFK activity 
compared to non-diabetic animals while Figure 3.14 shows that PFK expression is increased by 
250% in diabetic control animals compared to the non-diabetic control animals. This increase in 
PFK expression accompanying a decrease in activity might be as an attempt to overcome inhibition 
of PFK activity as suggested by Keildson et al. (2014) in a study involving muscle.  In diabetes, 
insulin secretion is reduced due to damaged β-cells. Reduced PFK activity of diabetic animals has 
also been observed in glycolytic tissues such as liver, skeletal muscle and heart (Da Silva et al., 
2010; Da Silva et al., 2012). Diminished PFK activity in skin has also been observed in 
immunocompromised animals (Gupta et al., 2004). The fructose-6-phosphate substrate used for 
PFK activity in diabetic animals possibly comes from increased glycogenolysis within the cell 
producing glucose-1-phosphate that is converted by phosphoglucose isomerase to yield fructose-
6-phospahte rather than directly from hexokinase phosphorylation of glucose entry through in 
glycolysis. Treatment of diabetic animals with OA increased PFK activity compared to diabetic 
control animals. The increased PFK activity may be due to increased fructose-6-phosphate 
intermediate required for PFK activity. This suggestion is supported by the reduced glycogen 
phosphorylase activity in animals treated with OA and increased glycogen synthase activity in 
animals treated with OA and insulin found in type-I diabetic animals treated with OA (Mukundwa 
et al., 2016a).The increased PFK expression in diabetic animals  might be an attempt to overcome 
PFK activity inhibition (Keildson et al., 2014). The same trend is seen in skeletal muscle of 
diabetic rats in Figure 3.13. Treatment of diabetic animals with OA reduces PFK expression. This 
may be because OA alleviated the need for PFK over expression thus no longer required to 
overcome the inhibition of PFK activity in diabetes. 
Figure 3.4B shows a 30% decrease in skin fructose-1,6-bisphospahatase activity of diabetic 
animals compared to non-diabetic animals. This may be attributed to reduced glucose production 
capability of skin. The activities of gluconeogenic enzymes FBPase and PEPCK have been shown  
to be 20 times lower in skin compared to the liver (Peters and White, 1976). However, Peters and 
White (1976) suggested that FBPase does not necessarily contribute towards glucose metabolism 
through gluconeogenesis, but also through other pathways. Such a role has been seen in muscle 
where FBPase participates in glucose homeostasis where its product is isomerized and used as a 




cycle activity and hence less intermediates products are available for FBPase activity. FBPase may 
also have an entirely different function in skin not related to gluconeogenesis. This has been 
observed in muscle FBPase enzyme which  is involved in interacting with mitochondrial proteins 
(Gizak et al., 2012). Treatment of animals with OA lowered FBPase activity in both non-diabetic 
and diabetic animals. This suggests that OA lowers FBPase activity through other mechanisms 
that are not involved with metabolic changes caused by diabetes. 
In diabetes, there is reduced glycogen formation due to low insulin levels produced by STZ 
destroyed β-cells (Szkudelski, 2001). However, in this study, muscle glycogen content increased 
in diabetic control animals compared to non-diabetic animals (Table 3.1). OA treated non-diabetic 
animals showed a significant (p < 0.05) 122% increase in glycogen content compared non-diabetic 
control animals. Similarly, 41% increase in glycogen content was seen in OA treated diabetic 
animals compared to diabetic control animals. This agrees with other studies that have also showed 
that OA can increase glycogen content in both non-diabetic and diabetic animals (Musabayane et 
al., 2010; Ngubane et al., 2011). These results correlate with the increase in hexokinase activity in 
OA treated diabetic animals seen in Figure 3.1 above. OA is therefore able to reduce 
hyperglycaemia by regulating glycogen metabolism possibly by modulating activity of 
glycogenesis regulatory enzymes. OA may also enhance insulin action of remaining β-cells thus 
stimulating glycogen formation. This concept is supported by the increase in glycogen synthase 
activity while reducing glycogen phosphorylase activity in the presence of insulin in OA-treated 
type-I diabetic animals (Mukundwa et al., 2016b). 
There was no difference in glycogen content observed between skin of non-diabetic and diabetic 
animals (Table 3.1). However, Mukundwa et al. (2016a) showed that glycogen content is reduced 
in a type-I diabetic model. Both OA treated non-diabetic and diabetic animals had reduced 
glycogen content compared to their respective untreated control groups. The decrease in glycogen 
in both these groups suggests that OA might induce glycogen break down in skin of diabetic 
animals. The increase in glycogen breakdown regulated by glycogen phosphorylase may be a way 
of providing free glucose to be channeled towards energy formation during diabetes. As mentioned 
by previous studies and suggested in this study, OA increases glycogen content in muscle of 
diabetic animals (Musabayane et al., 2010; Ngubane et al., 2011). However, this phenomenon is 




be the same as seen in skeletal muscle. In type-I diabetes, OA and insulin treated animals showed 
no significant changes in glycogen content in skin compared to their control animals (Mukundwa 
et al., 2016a). Therefore, OA might have different effects depending on model of diabetes and 
tissue. 
 
Effects of CA treatment in diabetic animals 
 
A high fat-STZ model is a common model used to induce a non-genetic type-II diabetes 
(Srinivasan et al., 2005). However, although the high fat diet induces insulin resistance, it requires 
complicated dietary formulations (Srinivasan et al., 2005). Some studies have argued that low 
doses of just 40 mg/kg b.w. STZ may not be effective in inducing type-II diabetes while higher 
doses (45-50 mg/kg b.w) can cause the animal to resemble type-I rather than type-II diabetes. STZ 
alone does not induce insulin resistance rather it selectively destroys pancreatic cells subsequently 
causing hyperglycemia and subsequently only inducing insulin insufficiency (Srinivasan et al., 
2005). Studies have shown that feeding animals with 10-15% fructose over a short or long period 
induces insulin resistance (Dai et al., 1994; Hininger-Favier et al., 2009). Therefore, when fructose 
feeding is coupled with a low dose of STZ it can induce both hyperglycemia and insulin resistance 
(Wilson and Islam, 2012). In this study, animals were given 10% fructose ad libitum for two weeks 
before being given a 40 mg/kg b.w. STZ injection to produce an insulin insufficiency and insulin 
resistance model of type-II diabetes. Insulin resistance results in defects in glucose uptake, 
phosphorylation, glucose oxidation and reduced glycogen synthesis in skeletal muscle (Petersen 
and Shulman, 2002). 
Figure 3.5 shows that hexokinase activity is reduced by 13.4% in skeletal muscle of diabetic 
animals compared to non-diabetic animals. This observation is similar to those obtained from other 
studies in both Type-I and -II diabetic models (Ngubane et al., 2011; Ramachandran and 
Saravanan, 2013). The lack of insulin sensitivity in skeletal muscle causes an impairment of 
peripheral glucose uptake and utilization. Glucose uptake by GLUT4 transporter is also impaired 
where both translocation and activity of transporter are diminished (Williams et al., 2001; Karlsson 
and Zierath, 2007). Defects in intracellular glucose uptake also play a role in reducing hexokinase 




hexokinase action. Reduced glucose phosphorylation by hexokinase causes a decrease in glucose 
metabolism and an increase in blood glucose levels in diabetic animals. Treatment of diabetic 
animals with 500 mg/kg b.w. of CA increased hexokinase activity by 4.4% while treatment with 
1000 mg/kg b.w. of CA and metformin decreased hexokinase activity by 11.1% and 11.7% 
respectively. Increase in hexokinase activity in diabetic animals treated with 500 mg/kg b.w. of 
CA implies that CA may facilitate or stimulate glucose entry into the cell by targeting translocation 
and activation of glucose transporter, GLUT4. CA might also reduce insulin resistance in skeletal 
muscle promoting signaling of glucose uptake and subsequent phosphorylation by insulin sensitive 
enzyme, hexokinase. The results indicate that lower concentrations of CA are required for the 
extract to act on skeletal muscle as D+500 yielded an increase in hexokinase activity while D+1000 
decreased activity. This suggests that lower doses of CA may be more effective in affecting against 
hexokinase activity while higher doses activate hexokinase activity. Asiatic acid, a triterpene of 
CA has also been shown to reduce hexokinase activity of type-II diabetic animals (Ramachandran 
and Saravanan, 2013). 
The effects of CA on PFK activity and expression in skeletal muscle is shown in Figures 3.6A and 
3.15 respectively. PFK is a key control point in glycolysis regulation and is diminished in skeletal 
muscle of diabetic animals. In this study PFK activity was reduced by 87% in diabetic animals 
compared to non-diabetic animals. In contrast, PFK expression was increased in diabetic control 
animals compared to non-diabetic control animals. PFK is not directly affected by insulin 
resistance, rather the reduced of response of skeletal muscle to insulin affects the insulin signaling 
pathway thus preventing the phosphorylation of PFK (Vestergaard et al., 1993). It has been shown 
that PFK is regulated by different protein kinases that phosphorylate its tyrosine and serine 
residues on PFK in erythrocytes (Real-Hohn et al., 2010). The decrease in hexokinase activity also 
directly brings about diminished PFK activity as the intermediate product, glucose-6-phosphate is 
required for isomerization to fructose-6-phosphate before it can act as a substrate for PFK. This 
decrease in hexokinase activity is also observed in diabetic animals in Figure 3.5 of the OA study 
which involved an insulin insufficiency model of diabetes. As suggested above, the increase in 
PFK expression may be a mechanism to compensate for PFK activity inhibition. The same trend 
of increased PFK expression was seen in insulin insufficient type-II diabetic model of muscle in 
Figure 3.13. Treatment of diabetic animals with CA (500 and 1000 mg/kg b.w.) and metformin 




reduced compared to diabetic control animals. The increase in PFK activity and reduction of 
expression seen in CA suggests that CA can reduce or overcome insulin resistance thus increasing 
PFK activity of diabetic animals. CA may also stimulate re-association of PFK oligomeric 
structure into stable tetramers restoring balance between inactive dimers and active tetramers thus 
increasing its catalytic activity (Luther et al., 1986; Zancan et al., 2008). A lower dose of CA 
resulted higher PFK activity further showing that CA may be a potent glycolytic activator at low 
doses. 
Since skeletal muscle is not a gluconeogenic tissue, a lower (26%) decrease in FBPase activity 
was observed in diabetic animals (Figure 3.6B) In a gluconeogenic tissue such as liver, FBPase 
and PEPCK activities increase in diabetic animals due to increased endogenous glucose production 
to compensate for lack of glucose entry into cell (Srinivasan et al., 2014). Treatment of diabetic 
animals with 500 mg/kg b.w. of CA increased FBPase activity by 98% but treatment with 1000 
mg/kg b.w. of CA and metformin showed a 4.8% and 12% increase in activities respectively 
suggesting CA might increase insulin sensitivity the same way metformin does. Reduction of 
blood glucose levels in diabetic animals treated with metformin has been observed in alloxan 
induced type-I diabetic animals (Rahman et al., 2012). 
Epidermal skin tissue requires insulin for proliferation and differentiation and development of 
keratinocytes using insulin receptors (Wertheimer et al., 2001).The Skin also requires insulin for 
migration and differentiation in keratinocytes during wound healing (Liu et al., 2009). Diabetic 
animals showed a 20% and 57% decrease in hexokinase and phosphofructokinase activity 
respectively in skin compared to non-diabetic animals (Figures 3.7 and 3.8A). Figure 3.16 shows 
the expression of PFK is increased in diabetic control animals compared to non-diabetic animals. 
A similar decrease in hexokinase activity has been observed in skin of type-I diabetic animals 
(Mukundwa et al., 2016a). This decrease occurs due to reduced response to insulin by the skin. 
The skins’ degree of insulin response is unclear, but insulin receptor substrate proteins have been 
observed in skin keratinocytes (Shen et al., 2000). The lack of insulin receptor (IR) caused elevated 
blood glucose levels in IR-null keratinocytes (Spravchikov et al., 2001). In IR-null keratinocytes, 
the IGF-I receptor also shows reduced phosphorylation and reduced GLUT1 expression 
consequently resulting in reduced glucose uptake (Spravchikov et al., 2001). The decrease in 




effect on PFK activity of diabetic animals. Impaired hexokinase and phosphofructokinase activity 
in skin is also seen in immunocompromised and aging animals (Gupta et al., 2004). Treatment of 
diabetic animals with 500 mg/kg b.w. of CA increased hexokinase and PFK activity by 11% and 
35% respectively. In contrast, the expression of PFK in diabetic animals decreased upon treatment 
with both concentrations of CA. CA may increase hexokinase activity to protect skin cells from 
hyperglycaemia induced skin damage similar to its hepatoprotective mechanism (Antony et al., 
2006). CA has also been shown to be effective in enhancing skin healing properties by increasing 
collagen formation (Shukla et al., 1999; Somboonwong et al., 2012). CA may ameliorate changes 
in IGF-I receptor phosphorylation and GLUT-1 expression during diabetes resulting in more 
glucose being transported into cells for phosphorylation by hexokinase and subsequently 
phosphofructokinase enzymes. CA may also reduce PFK expression by directly acting on the 
PFKM gene. A similar reduction in PFK expression is seen in skin of diabetic animals treated with 
OA in the type-II insulin insufficiency model; and also in muscle of diabetic animals treated with 
CA in the insulin resistance and insulin insufficiency model in this study. 
Figure 3.8B Shows the effects of CA on FBPase activity in skin of non-diabetic and diabetic 
animals. A 36% decrease in FBPase activity is seen in diabetic animals compared to non-diabetic 
animals. A similar decrease in activity is observed in the insulin insufficiency type-II diabetic 
model in Figure 3.4B. This further suggests that FBPase activity may be involved in other 
mechanisms beyond glucose regulation. Treatment of diabetic rats with 500 mg/kg b.w. of CA and 
metformin increased FBPase activity by 7% and 61% respectively while treatment with 1000 
mg/kg b.w. decreased enzyme activity by 12%. CA may alter FBPase activity though other 
mechanisms not involved in glucose metabolism. 
Excess glucose is stored in liver and muscle as glycogen but glycogen has also been observed to 
be present in skin epidermis (Jensen et al., 2012). The presence of glycogen observed in epidermis 
is thought to be play a role in the hair cycle, sweat production and skin keratinization (Montagna 
et al., 1951; Adachi, 1961). Reduced glycogen content in response to starvation has been observed 
in tail skin of mice (Harmon and Phizackerley, 1983). Glycogen accumulation in response to injury 
and abnormal cell proliferation has also been observed in epidermis and keratinocytes respectively 
(Lobitz and Holyoke, 1954; Wertheimer et al., 2001). A 15% increase in glycogen content of 




Treatment with CA reduced glycogen levels suggesting that CA may ameliorate changes caused 
by diabetes in glycogen metabolism. 
Glycogen isolated from dog skin suggested the presence of GP and GS activity in this tissue 
(Adachi, 1961). In this study, no statistical difference in GS activity was observed between non-
diabetic and diabetic animals (Figure 3.9). These results are similar to those observed in a type-I 
diabetic model reported by Mukundwa et al. (2016a). Treatment with 500 mg/kg b.w. of CA 
increased GS activity this may be due to accumulated G-6-P from increased hexokinase activity 
seen in Figure 3.6A. CA may protect β-cells from STZ induced damage seen in triterpene, asiatic 
acid, which preserves β-cell mass and reduces hyperglycaemia in STZ-induced type-I diabetic 
animals (Liu et al., 2010). Asiatic acid also promotes survival of remaining β-cells by activating 
cell survival signaling. This occurs by activating protein kinase B in islets which plays a role in 
signaling cell death or survival (Liu et al., 2010). 
The skin of diabetic animals showed a reduction in glycogen phosphorylase activity (Figure 3.10) 
accompanied by an increase in glycogen content levels (Table 3.2). This implies that less glycogen 
is broken down resulting more of the glucose being stored than used up in skin of diabetic animals. 
A similar reduction in glycogen phosphorylase and increase in glycogen content has been observed 
in skin of type-I diabetic animals (Mukundwa et al., 2016a). In diabetes, liver glycogen 
phosphorylase is enhanced thus increasing the rate of glycogenolysis to contribute towards hepatic 
glucose production and reducing liver glycogen content (Docsa et al., 2011). Increase in glycogen 
levels have been observed in a variety of skin diseases and wound healing processes (Steiner, 
1955). Glycogen content may not necessarily be for glucose production like in gluconeogenic 
tissue but may be for energy production within the skin during stressful conditions such as diabetes 
and wound repair. Treatment of diabetic animals with both concentrations of CA increased GP 
activity while reducing glycogen content compared to non-diabetic animals. The increase in GP 
activity may be due to GS levels returning to normal (Figure 3.9) after treatment thus no need to 
compensate for reduced glycogen synthesis allowing glycogenolysis to return to its normal rate in 
skin. In epidermis GS and GP occur at equal rates thus maintaining a specific concentration of 
glycogen (Halprin and Ohkawara, 1966a). 
Serum AST and ALT enzymes are considered as biomarkers of tissue damage particularly the 




cytosol of liver into the bloodstream resulting from damaged liver due to defects in glucose 
utilization (Murali et al., 2013). Table 3.3 shows that ALT and AST levels are elevated by 17.6% 
and 7.7%, respectively in diabetic animals compared to non-diabetic animals. High levels of serum  
ALT are associated with decreased insulin sensitivity in the liver and considered as a marker for 
the potential risk of type-II diabetes (Vozarova et al., 2002). Vozarova et al. (2002) suggested that 
these high ALT levels indicate that the liver may play a potential role in pathogenesis of diabetes. 
Hyperglycaemia results in increased formation of reactive oxygen species in mitochondria 
subsequently resulting in oxidative stress causing tissue damage (Fiorentino et al., 2013). Increase 
in oxidative stress also slows down the pentose phosphate pathway which affects the concentration 
of NADPH thus causing more diabetic complications (Giacco and Brownlee, 2010). G-6-P, the 
substrate required for pentose phosphate pathway is provided by hexokinase. Thus, changes in 
hexokinase activity seen in skeletal muscle and skin may also indirectly contribute towards liver 
damage. Treatment of diabetic animals with 500 and 1000 mg/kg b.w. of CA lowered AST by 
17.3% and 18.7% respectively. ALT was lowered by 41% and 29.2% following treatment of 
diabetic animals with 500 and 1000 mg/kg b.w. of CA respectively. The ability of CA to lower 
these enzymes suggests that CA may protect animals from liver damage. These results are in 
agreement with those reported by Ramachandran and Saravanan (2013) using asiatic acid, a 
triterpene present in CA. 
The reduction of muscle mass and altered physical capacity has been documented in diabetic 
animals (Andersen et al., 2005). Both morphometric and statistical results show a decrease in 
muscle fibre thickness and diameter in diabetic animals compared to the non-diabetic control 
animals (Figure 3.18 and Table 3.4). Morphological studies revealed muscle fibres with distorted 
striations, reduction in the number of peripheral nuclei and increased spaces between muscle 
fibres. Statistical analysis showed a reduction in muscle fibre thickness and diameter of 16% and 
10% respectively. These results are in agreement with those reported by other studies (Cotter et 
al., 1993; Aughsteen et al., 2006; Mostafa, 2008). The decrease in muscle fibre thickness is 
reported to be due to a reduction of protein synthesis and increased protein degradation (Cotter et 
al., 1989). Apart from distorted muscle fibres, other structural changes observed include damaged 
myofibrils, distorted sarcomere Z line and swollen irregular mitochondria are as from electron 
microscopy (Mostafa, 2008). Increased inflammatory cells in response to damaged myofibrils has 




increased the number of peripheral nuclei and reduced space between connective tissue. Muscle 
fibre thickness was improved by 44%, 23% and 2% in diabetic animals treated with 500 mg/kg 
b.w. of CA, 1000 mg/kg b.w. of CA and metformin respectively. Muscle fibre diameter was also 
improved by 10%, 11% and 5% in diabetic animals treated with CA (500 and 1000 mg/kg b.w.) 
and metformin respectively. Treatment with CA may have ameliorated morphological changes and 
muscle fibre thickness by enhancing insulin sensitivity in skeletal muscle as treatment of diabetic 
rats with insulin is said to improve structural changes and subsequently protein synthesis (Moore 
et al., 1983). CA may also protect skeletal muscle from hyperglycaemia thus reducing damage 
caused by diabetes.  
At least 30% of diabetic patients experience some form of dermatological complications. The 
results in Figures 3.19, 3.20 and Table 3.5 indicate the morphological and statistical effects of CA 
in non-diabetic and diabetic skin. Diabetic animals showed a thinner epidermal layer and reduced 
connective tissue (Figure 3.20). The thinner epidermis was mainly due to reduced spinous layer 
rather than all the other layers that make up the epidermis. Similar results have been observed in 
other studies (Tanga et al., 2003). Other structural changes observed by other studies include 
deeply stained nuclei and increased pixel intensity of collagen (Omar, 2010; Knas et al., 2013). 
Immunohistochemical changes observed include reduction of CD34 percentage (Omar, 2010). 
Treatment of diabetic animals with CA ameliorated changes in skin structure. This further suggests 
that CA protects skin from structural changes caused by diabetes. CA has also been shown to be 
effective in enhancing skin healing properties by increasing collagen formation (Shukla et al., 







OA and CA have hypoglycaemic effects in insulin insufficient and insulin resistant type-II diabetic 
models respectively. OA increased hexokinase and phosphofructokinase activity in skeletal 
muscle and skin of diabetic rats. This suggests that OA might modulate its hypoglycaemic activity 
in skeletal muscle by regulating glycolysis. OA also reduced excessive PFK expression in skin of 
diabetic animals suggesting OA may have modulating activity and expression of glycolytic 
enzymes. A 500 mg/kg b.w. dose of CA increased hexokinase, PFK and GS activity while reducing 
PFK expression in skeletal muscle and skin of diabetic animals and hence may reduce 
hyperglycaemia by controlling glycolysis and glycogen synthesis. This study also suggests that a 
lower concentration of 500 mg/kg b.w dose of CA is enough to potentiate its hypoglycaemic 
activity while a higher dose of 1000 mg/kg b.w. is inhibitory. CA might be able to protect tissues 
from damage caused by diabetes as it reduced AST and ALT levels in diabetic animals. 
Histological changes in muscle and skin caused by diabetes were decreased after treatment with 
diabetes further confirming tissue protective capabilities of CA. 
 
Limitations and further studies 
The limitations of this study were that that FBPase was the only gluconeogenic enzyme 
investigated and Western blots of only PFK and GS were performed. Studies on OA also require 
more assays on gluconeogenic rate limiting enzyme PEPCK and glycogenic enzymes GS, and GP 
in both skeletal muscle and skin. Western blot procedures on HK, FBPase and PEPCK expression 
studies should be explored in both OA and CA studies. Further studies  should  also involve Gas 
Chromatography mass spectrometry investigation of the chemical profile of the methanol extract 
of CA. Chronic studies on OA and CA should be done to investigate the long-term effects of both 
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